[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 109
1. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
  • BACKGROUND: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
  • This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited.
  • Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC.
  • MATERIALS AND METHODS: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Twelve patients were staged III and 20 were metastatic (10 recurrent).
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • The median time to progression was 4.2 months and median duration of survival was 9.8 months.
  • Eight patients (25%) had a G 3-4 neutropenia, while G 3-4 anaemia was observed in 2 patients and thrombocytopenia in 1 patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Quinazolines / adverse effects. Survival Rate. Thiophenes / administration & dosage. Thiophenes / adverse effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


2. Silveira NJ, Varuzza L, Machado-Lima A, Lauretto MS, Pinheiro DG, Rodrigues RV, Severino P, Nobrega FG, Head and Neck Genome Project GENCAPO, Silva WA Jr, de B Pereira CA, Tajara EH: Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genomics; 2008;1:56
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries.
  • BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies in humans.
  • When detected early, HNSCC has a good prognosis, but most patients present metastatic disease at the time of diagnosis, which significantly reduces survival rate.
  • METHODS: Aiming to identify differentially-expressed genes involved in laryngeal squamous cell carcinoma (LSCC) development and progression, we generated individual Serial Analysis of Gene Expression (SAGE) libraries from a metastatic and non-metastatic larynx carcinoma, as well as from a normal larynx mucosa sample.
  • RESULTS: Statistical data analysis identified a subset of 1,216 differentially expressed tags between tumor and normal libraries, and 894 differentially expressed tags between metastatic and non-metastatic carcinomas.
  • Three genes displaying differential regulation, one down-regulated (KRT31) and two up-regulated (BST2, MFAP2), as well as one with a non-significant differential expression pattern (GNA15) in our SAGE data were selected for real-time polymerase chain reaction (PCR) in a set of HNSCC samples.
  • Consistent with our statistical analysis, quantitative PCR confirmed the upregulation of BST2 and MFAP2 and the downregulation of KRT31 when samples of HNSCC were compared to tumor-free surgical margins.
  • As expected, GNA15 presented a non-significant differential expression pattern when tumor samples were compared to normal tissues.
  • CONCLUSION: To the best of our knowledge, this is the first study reporting SAGE data in head and neck squamous cell tumors.
  • Statistical analysis was effective in identifying differentially expressed genes reportedly involved in cancer development.
  • The differential expression of a subset of genes was confirmed in additional larynx carcinoma samples and in carcinomas from a distinct head and neck subsite.
  • This result suggests the existence of potential common biomarkers for prognosis and targeted-therapy development in this heterogeneous type of tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1244-51 [15558013.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):789-97 [15499618.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):127-35 [15685196.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):182-6 [15640797.001]
  • [Cites] Physiol Genomics. 2002 Oct 29;11(2):37-44 [12407185.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):619-30 [11489919.001]
  • [Cites] Head Neck. 2001 Mar;23(3):238-53 [11428456.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):977-82 [11359384.001]
  • [Cites] Bioinformatics. 2000 Nov;16(11):953-9 [11159306.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):921-8 [10953016.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3220-4 [10918578.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):374-81 [10718422.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):151-68 [15657362.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8 [15655179.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8442-50 [15623624.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Dec;4(8):637-51 [15578920.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3697-704 [15292061.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 [10329429.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14661-5 [7514177.001]
  • [Cites] Nature. 1993 Dec 2;366(6454):473-5 [7902537.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):249-58 [15352037.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):89-96 [15221650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cell Mol Life Sci. 2004 Jun;61(11):1372-83 [15170515.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2484-98 [14676830.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):295-302 [15023835.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):418-26 [14969821.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):55-63 [14729608.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):429-35 [12964014.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3058-64 [12912957.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):760-70 [12874079.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):683-9 [12866027.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):259-68 [12618198.001]
  • [Cites] Oral Oncol. 2003 Apr;39(3):248-58 [12618197.001]
  • [Cites] Eur J Oral Sci. 2003 Feb;111(1):34-41 [12558806.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):159-62 [12429865.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8206-19 [12444558.001]
  • [Cites] Biol Direct. 2008;3:22 [18513408.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1482-94 [12237917.001]
  • [Cites] Head Neck. 2002 Sep;24(9):874-87 [12211052.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2634-40 [11965536.001]
  • [Cites] Cell Growth Differ. 2002 Apr;13(4):163-71 [11971816.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1184-90 [11861402.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6196-204 [11593428.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Hum Mol Genet. 2001 Sep 15;10(19):2133-41 [11590130.001]
  • [Cites] Cell Oncol. 2008;30(1):63-75 [18219111.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1971-82 [17043662.001]
  • [Cites] Biol Cell. 2006 Aug;98(8):479-90 [16608439.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):136-43 [16181731.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2860-8 [16574107.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10089-97 [16492672.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1024-39 [16205657.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):865-75 [15956244.001]
  • [Cites] Oral Oncol. 2005 Apr;41(4):365-74 [15792608.001]
  • (PMID = 19014460.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2629771
  • [Investigator] Curry PM; de Carvalho MB; Dias-Neto E; Figueiredo DL; Fukuyama EE; Góis-Filho JF; Leopoldino AM; Mamede RC; Michaluart-Junior P; Moreira-Filho CA; Moyses RA; Nóbrega FG; Nóbrega MP; Nunes FD; Ojopi EP; Okamoto OK; Serafini LN; Severino P; Silva AM; Silva WA Jr; Silveira NJ; Souza SC; Tajara EH; Wünsch-Filho V; Zago MA; Amar A; Arap SS; Araújo NS; Araújo-Filho V; Barbieri RB; Bandeira CM; Bastos AU; Braconi MA; Brandão LG; Brandão RM; Canto AL; Carmona-Raphe J; Carvalho-Neto PB; Casemiro AF; Cerione M; Cernea CR; Cicco R; Chagas MJ; Chedid H; Chiappini PB; Correia LA; Costa A; Costa AC; Cunha BR; Curioni OA; Dias TH; Durazzo M; Ferraz AR; Figueiredo RO; Fortes CS; Franzi SA; Frizzera AP; Gallo J; Gazito D; Guimarães PE; Gutierres AP; Inamine R; Kaneto CM; Lehn CN; López RV; Macarenco R; Magalhães RP; Martins AE; Meneses C; Mercante AM; Montenegro FL; Pinheiro DG; Polachini GM; Porsani AF; Rapoport A; Rodini CO; Rodrigues AN; Rodrigues-Lisoni FC; Rodrigues RV; Rossi L; Santos AR; Santos M; Settani F; Silva FA; Silva IT; Silva-Filho GB; Smith RB; Souza TB; Stabenow E; Takamori JT; Tavares MR; Turcano R; Valentim PJ; Vidotto A; Volpi EM; Xavier FC; Yamagushi F; Cominato ML; Correa PM; Mendes GS; Paiva R; Ramos O; Silva C; Silva MJ; Tarlá MV
  •  go-up   go-down


3. Klune JR, Zuckerbraun B, Tsung A: Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report. Int Semin Surg Oncol; 2010;7(1):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated skeletal muscle metastasis following successful treatment of laryngeal cancer: case report.
  • We report here on a patient that had been previously treated for squamous cell laryngeal cancer with surgical resection and adjuvant systemic chemotherapy that presented with a metastasis to the rectus abdominis muscle without evidence of recurrent disease at the primary site.
  • After a metastatic workup with PET/CT scan suggested this to be an isolated lesion, surgical excision with negative margins was performed based upon limited treatment options secondary to the location of the tumor and his favorable prognosis suggested by his pathological staging at the time of the initial resection.
  • Here we discuss the incidence of distant metastases from laryngeal cancer and appropriate screening methods.
  • Additionally, skeletal muscle metastases and treatment considerations are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 1):397-401 [10718426.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Dec;11(6):375-8 [11822863.001]
  • [Cites] J Laryngol Otol. 2003 Jan;117(1):85-7 [12590867.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):412-21; discussion 421-2 [14501507.001]
  • [Cites] Endoscopy. 2004 May;36(5):472 [15100974.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Sep;131(3):321-3 [15365554.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 May-Jun;28(3):377-80 [15886946.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):708-11; quiz 752, 753 [16246684.001]
  • [Cites] J Laryngol Otol. 2005 Oct;119(10):784-90 [16259655.001]
  • [Cites] Clin Exp Dermatol. 2006 Mar;31(2):242-4 [16487102.001]
  • [Cites] Top Magn Reson Imaging. 2007 Jun;18(3):193-202 [17762383.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):401-3 [19235784.001]
  • [Cites] Head Neck. 1997 Sep;19(6):500-5 [9278758.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1361-5 [9788864.001]
  • [Cites] Head Neck. 2000 Oct;22(7):680-6 [11002323.001]
  • (PMID = 20187979.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2838919
  •  go-up   go-down


Advertisement
4. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope; 2009 Aug;119(8):1518-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 variant isoforms in head and neck squamous cell carcinoma progression.
  • The objective of this study was to investigate the role of the CD44 v3, v6, and v10 variant isoforms in head and neck squamous cell carcinoma (HNSCC) tumor progression behaviors.
  • STUDY DESIGN: Laboratory study involving cell cultures and clinical tissue specimens.
  • METHODS: Analysis of the expression of standard CD44s and the CD44 variant isoforms v3, v6, and v10 was carried out in the HNSCC cell line, HSC-3.
  • Immunohistochemical analysis was performed on clinical tissue specimens obtained from a series of 82 HNSCC patients.
  • The expression of standard CD44s and the CD44 v3, v6, and v10 variants in primary tumor specimens (n = 82) and metastatic cervical lymph nodes (n = 24) were analyzed with respect to various clinicopathologic variables.
  • RESULTS: HSC-3 cells express at least four CD44 isoforms, and these CD44 isoforms mediate migration, proliferation, and cisplatin sensitivity.
  • Compared with primary tumors, a greater proportion of metastatic lymph nodes demonstrated strong expression of CD44 v3 (lymph node 14/24 vs. primary tumor 38/82), CD44 v6 (lymph node 18/24 vs. primary tumor 26/82), and CD44 v10 (lymph node 14/24 vs. primary tumor 16/82), while expression of standard CD44 was not significantly different in metastatic lymph nodes and primary tumors (lymph node 10/24 vs. primary tumor 60/82).
  • CD44 v6 and CD44 v10 were also significantly associated with shorter disease-free survival.
  • Furthermore, expression of certain CD44 variants may be important molecular markers for HNSCC progression and should be investigated as potential therapeutic targets for therapy.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 Mar;85(4):514-8 [10691836.001]
  • [Cites] Semin Cancer Biol. 2008 Aug;18(4):251-9 [18450475.001]
  • [Cites] Jpn J Cancer Res. 2000 Apr;91(4):410-5 [10804289.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1088-95 [11014576.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1217-23 [11031408.001]
  • [Cites] Tumour Biol. 2001 Jan-Feb;22(1):45-53 [11054026.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):115-20 [11223837.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):426-32 [11283501.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5275-83 [11431370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):628-35 [11764382.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4067-72 [11751503.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48679-92 [11606575.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] J Lab Clin Med. 2002 Jan;139(1):59-65 [11873246.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2059-64 [12209509.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):745-7 [12213700.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25285-8 [12738783.001]
  • [Cites] Auris Nasus Larynx. 2004 Mar;31(1):35-41 [15041052.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):102-18 [15051494.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26991-7007 [15090545.001]
  • [Cites] Exp Mol Pathol. 2004 Aug;77(1):18-25 [15215046.001]
  • [Cites] Front Biosci. 1998 Jul 1;3:d637-49 [9634539.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] J Exp Med. 1993 Feb 1;177(2):443-55 [8426113.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):127-33 [7529235.001]
  • [Cites] J Pathol. 1996 May;179(1):66-73 [8691348.001]
  • [Cites] J Cell Physiol. 1997 May;171(2):152-60 [9130462.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):206-15 [9618160.001]
  • [Cites] Front Biosci. 1999 Jan 1;4:A1-8 [9872731.001]
  • [Cites] Cell Motil Cytoskeleton. 1999;43(4):269-87 [10423269.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):837-45 [10446451.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24 [16415424.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14026-40 [16565089.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1356-65 [16557236.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):771-8 [16847188.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1163-8 [16855392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8 [17372087.001]
  • [Cites] Head Neck. 2007 Jun;29(6):550-8 [17252589.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] J Cell Physiol. 2000 May;183(2):182-95 [10737894.001]
  • (PMID = 19507218.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA066163-14; United States / NCI NIH HHS / CA / R01 CA078633-10; United States / NIAMS NIH HHS / AR / P01 AR039448-190007; United States / NCI NIH HHS / CA / CA078633-10; United States / NCI NIH HHS / CA / R01 CA066163-14; United States / NCI NIH HHS / CA / R01 CA66163; United States / NIAMS NIH HHS / AR / P01 AR039448; United States / NCI NIH HHS / CA / R01 CA078633; United States / NIAMS NIH HHS / AR / AR039448-190007; United States / NIAMS NIH HHS / AR / P01 AR39448; United States / NCI NIH HHS / CA / R01 CA066163
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ NIHMS113866; NLM/ PMC2718060
  •  go-up   go-down


5. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • PERSPECTIVES: Head-and-neck cancer includes malignant tumours arising from a variety of sites in the upper aerodigestive tract.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The resulting recommendations were approved by the Report Approval Panel of the PEBC, and by the Head and Neck Cancer DSG.
  • Only four phase iii trials met the inclusion criteria for the present guideline.
  • No practice guidelines, systematic reviews, or meta-analyses were found during the course of the literature search.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • PRACTICE GUIDELINE: These recommendations apply to adult patients with locally advanced (nonmetastatic stages iii-ivb) or recurrent or metastatic (stage IVC) HNSCC.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • QUALIFYING STATEMENTS: Chemoradiation is the current standard of care for patients with locally advanced HNSCC, and to date, there is no evidence that compares cetuximab plus radiotherapy with chemoradiation, or that examines whether the addition of cetuximab to chemoradiation is of benefit in these patients.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).
  • As compared with methotrexate, gefitinib was associated with an increased incidence of tumour hemorrhage (8.9% for 250 mg and 11.4% for 500 mg daily vs. 1.9% for weekly methotrexate).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


6. Morales-Puebla JM, Toro-Rojas M, Segura-Saint-Gerons R, Fanego-Fernández J, López-Villarejo P: Basaloid squamous cell carcinoma: report of five cases. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e451-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: report of five cases.
  • OBJECTIVES: To document the clinical and histopathological characteristics of basaloid squamous cell carcinoma (BSCC).
  • CASES: retrospective review of five cases with the diagnosis of BSCC of the larynx.
  • Surgery supplemented with radiation was used in three patients, partial surgery was used in another case and radiation and associated chemotherapy in the other one.
  • Two cases were found to have metastatic lymph nodes.
  • Central comedonecrosis within the cells nests, cell with nuclear palisading and high-grade dysplasia in overlaying mucosa are the main characteristics.
  • [MeSH-major] Carcinoma, Squamous Cell. Laryngeal Neoplasms
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038913.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


7. Choong N, Vokes E: Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin; 2008 Jan-Feb;58(1):32-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expanding role of the medical oncologist in the management of head and neck cancer.
  • The multidisciplinary approach to treating squamous cell carcinoma of the head and neck is complex and evolving.
  • This article aims to review some recent developments in squamous cell carcinoma of the head and neck, in particular the expanding role of chemotherapy in its management.
  • Surgery and radiotherapy have remained the mainstay of therapy.
  • Chemotherapy is increasingly being incorporated into the treatment of squamous cell carcinoma of the head and neck.
  • Previously, radiotherapy following surgery was the standard approach to the treatment of locoregionally advanced resectable disease.
  • Induction chemotherapy has been useful in resectable disease where organ preservation is desirable, but this approach was inferior for the goal of larynx preservation, while leading to similar survival when compared with concomitant chemoradiotherapy.
  • There is recent evidence that taxanes added to induction chemotherapy with cisplatin and fluorouracil result in improved survival outcomes.
  • Novel targeted agents, such as epidermal growth factor receptor antagonists, are showing promise in the treatment of patients with both locoregionally advanced and recurrent/metastatic squamous cell carcinoma of the head and neck.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Alcohol Drinking / adverse effects. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Papillomavirus Infections / complications. Physician's Role. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096865.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 206
  •  go-up   go-down


8. Kawecki A, Jagielska B, Falkowski S: [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results]. Otolaryngol Pol; 2000;54 Suppl 31:21-3
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for metastatic or recurrent laryngeal cancer: tolerance and early results].
  • In the Head and Neck Cancer Department of Cancer Centre in Warsaw between 1994 and 1998 fifty three patients with recurrent or metastatic laryngeal cancer were treated with methotrexate-based chemotherapy.
  • Chemotherapy protocol consist of methotrexate, vinblastine, 5-fluorouracil, bleomycin, cyclophosphamide and steroids used every two weeks.
  • Before treatment, unresectable local recurrence was observed in 35 patient and distant secondaries in 18 others.
  • Tolerance of treatment was acceptable.
  • Partial regression of the tumor was obtained in 30% of patients.
  • Presented program is an effective alternative to supportive treatment in patients with recurrent or metastatic laryngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974834.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


9. Haigentz M Jr, Silver CE, Hartl DM, Takes RP, Rodrigo JP, Robbins KT, Rinaldo A, Ferlito A: Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin Pharmacother; 2010 Jun;11(8):1305-16
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy regimens and treatment protocols for laryngeal cancer.
  • IMPORTANCE OF THE FIELD: Laryngeal cancer has been the model of curative-intent organ-preserving therapies in clinical oncology.
  • Although the optimal care of patients with laryngeal cancer is truly multidisciplinary, with progressive advances in surgical, radiation, and medical oncology, the development of effective systemic therapies has been a major component of the therapeutic arsenal against laryngeal cancer.
  • AREAS COVERED IN THIS REVIEW: This review will discuss the rapidly evolving roles of chemotherapy in the management of locally advanced and metastatic laryngeal cancer.
  • WHAT THE READER WILL GAIN: The reader will gain a historical perspective on this evolution in treatment and will appreciate current treatment challenges and promising future directions in optimizing therapeutic efficacy in functional larynx preservation and in patient survival.
  • TAKE HOME MESSAGE: The treatment of most patients with laryngeal cancer with systemic therapy represents an opportunity to positively impact functional outcomes with an anatomically and functionally preserved larynx.
  • Future challenges include identification of novel therapies and optimizing therapy protocols for individualized patient care.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Interdisciplinary Communication. Medical Oncology. Pathology, Molecular. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429666.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  •  go-up   go-down


10. Tanaka A, Ohsawa H, Ikeda H, Koshiba R: [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina]. Kyobu Geka; 2002 Jul;55(7):537-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
  • A 64-year-old male, who had received successful radiotherapy for the previous laryngeal cancer, was admitted to our department for the treatment of a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina.
  • The endotracheal biopsy of the carinal tumor demonstrated squamous cell carcinoma, though preoperative examination of the intrapulmonary tumor was unable to clarify it's pathological type.
  • The intrapulmonary tumor required right upper lobectomy and R2 lymph node dissection as a measure against the possibility of primary lung cancer.
  • Since the endotracheal cancer was diagnosed as an intra mucosal tumor by the preoperative computed tomography (CT) scans and the bronchoscopic examination, laser abrasion therapy to the endotracheal tumor was performed 4 days before the lobectomy of the intrapulmonary tumor.
  • After the pulmonary operation, the intrapulmonary tumor was diagnosed as squamous cell carcinoma without lymph node metastasis, and it was suggested to be a metastatic tumor of the previous laryngeal cancer.
  • Both radiotherapy to the carina and general chemotherapy with docetaxel hydrate and carboplatin were used as adjuvant therapies 36 days after the lobectomy.
  • One year after the pulmonary surgery, there is no recurrence of the tumor in the lung or carina.
  • Laser abrasion therapy to the endotracheal tumor is very useful and safe for the patient, who should then receive pulmonary resection soon after the therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Paclitaxel / analogs & derivatives. Pneumonectomy. Taxoids. Tracheal Neoplasms / surgery
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Laser Therapy. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12136580.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Scarpatetti M, Tsybrovskyy O, Popper HH: Cytokeratin typing as an aid in the differential diagnosis of primary versus metastatic lung carcinomas, and comparison with normal lung. Virchows Arch; 2002 Jan;440(1):70-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin typing as an aid in the differential diagnosis of primary versus metastatic lung carcinomas, and comparison with normal lung.
  • Due to more efficient chemotherapy protocols, the number of second and even third primary carcinomas is steadily increasing.
  • To denominate the possible origin of a carcinoma, different markers are available as an aid, e.g. hormones, proteins and lipoproteins, secretion products and cytoskeletal proteins.
  • As expected, immunohistochemical investigation gave no clear-cut results, but, with statistical analysis, lung adenocarcinomas could be separated from metastatic adenocarcinomas using CK 5 and 18 and HMW CK (specificity 92.5%, sensitivity 62.5%).
  • Lung clear cell carcinomas and large cell carcinomas with clear cell areas could be distinguished from metastatic renal clear cell carcinomas by the CK 7 staining reaction.
  • Squamous cell carcinomas of the lung and metastatic squamous cell carcinomas of the larynx, pharynx and oesophagus could not reliably be separated in part due to the few number of cases available.
  • CK polypeptide typing is thus an additional aid in the differential diagnosis of lung carcinomas versus carcinomas metastatic to the lung.
  • [MeSH-major] Keratins / classification. Lung / chemistry. Lung Neoplasms / chemistry. Lung Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / chemistry. Carcinoma, Squamous Cell / chemistry. Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11942579.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


12. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Germann N, Tubiana-Mathieu N: Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol; 2007 Jun;30(3):278-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
  • OBJECTIVES: This phase II study was conducted to assess the efficacy of docetaxel plus gemcitabine in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: Forty patients with pharynx or larynx cancer were included and treated with an intravenous infusion of docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 day 1 and day 8 every 3 weeks for 6 cycles.
  • RESULTS: Among the 40 patients included, 17 had metastatic disease and 18 had received prior chemotherapy.
  • Three treatment-related deaths due to infection were reported.
  • CONCLUSION: The docetaxel and gemcitabine combination is an active treatment of recurrent or metastatic head and neck cancer.
  • However, this regimen is associated with a high hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Laryngeal Neoplasms / drug therapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Recurrence. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551305.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G: Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol; 2010 Nov;46(11):818-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
  • The aim of the present study was to identify a potentially effective new treatment regimen for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in disease progression after at least two previous chemotherapy regimens.
  • The regimen was administered to patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with surgery, radiotherapy or both and progressing after at least two chemotherapy regimens.
  • Twenty-four patients with histologically confirmed tumors of oral cavity, oropharynx, hypopharynx and larynx were enrolled.
  • After 3 cycles of treatment 23 patients (95.8%) were evaluable for response: 4 patients had partial response; 12 stable disease and 7 progressive disease.
  • Disease control rate was 69.5%.
  • At a median follow-up of 21.3months, the median progression-free survival was 5.8months.
  • The present study shows that the combination of Vinorelbine and Cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck patients is effective, feasible and has a good safety profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Cetuximab. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20920877.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 5V9KLZ54CY / Vinblastine; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


14. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab; 2007 Sep;92(9):3466-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
  • CONTEXT: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course.
  • No effective systemic therapy is available.
  • OBJECTIVE: We investigated imatinib, a tyrosine kinase inhibitor, as a potential treatment in patients with disseminated MTC.
  • DESIGN: A phase II study was initiated using 600 mg imatinib daily with a possible dose increase to 800 mg in case of progression.
  • Standard Response Evaluation Criteria in Solid Tumors were used using computed tomography or magnetic resonance imaging every 2 months.
  • Three patients stopped treatment due to toxic effects [fatigue (n = 2) and nausea (n = 1)].
  • In four cases the dose of imatinib was decreased because of toxicity [rash and malaise (n = 2) and laryngeal swelling (n = 2)].
  • Emergency tracheotomy was performed in two cases due to mucosal swelling of the larynx in patients with recurrent nerve palsy and a narrow vocal cleft.
  • In nine patients with a history of a thyroidectomy, the dose of supplemental thyroid hormone was increased because of serious hypothyroidism.
  • CONCLUSIONS: Imatinib therapy yielded no objective responses and induced considerable toxicity in patients with MTC.
  • [MeSH-major] Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / pathology. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579194.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN13256080
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


15. Abo H, Tsukuda M, Matsuda H, Horiuchi C, Taguchi T, Watanabe M, Niho T: [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1707-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
  • We report two successful remnant and recurrent cases of head and neck cancer treated with S-1.
  • Case 1, a 52-year-old man, was diagnosed as supraglottic laryngeal carcinoma (T3N2cM0, squamous cell carcinoma: SCC) on January 25, 2000, and concurrent chemoradiotherapy (CCRT) was applied.
  • After the treatment, a remnant tumor in the larynx was found by biopsy.
  • Pulmonary metastasis was detected by chest CT on June 14, 2001, and the administration of S-1 was started.
  • After 2 courses, the mass in the lung disappeared, and the primary lesion was also judged to be a complete response(CR).
  • The administration of S-1 is still continuing and remnant tumors have not been found.
  • Case 2, a 76-year-old man, was diagnosed with hypopharyngeal carcinoma (T3N2bM0, SCC) on December 14, 2001, and CCRT was applied resulting in CR in the hypopharynx and the neck.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


21. Specenier PM, Lalami Y, Vermorken J, Lacombe D, El-Hariry I, Bogaerts J, Awada A: EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol; 2009 May 20;27(15_suppl):6017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC).
  • : 6017 Background: CRT is considered a standard approach for LA-LxHxSCC.
  • The addition of LAP was investigated in combination with a sequential therapeutic approach (IC→ CRT).
  • METHODS: Eligible tumors were SCCHN: T3-T4 larynx (Lx), T2-T4 hypopharynx (Hx) N0-3 M0.
  • RESULTS: Seven male patients were included; tumor sites: LX (n = 3) / Hx: (n = 4), median age 59 years (range: 47-79), WHO PS 0-1, no severe or uncontrolled comorbidity.
  • Renal toxicity was observed among these 3 pts (grade 4 [n = 1], grade 2 [n=1] and grade 1 [n=1]), with 1 DLT, leading to treatment interruption in this group.
  • As LAP plus cisplatinum plus RT was feasible in another study, a second cohort was conducted in 4 pts, receiving LAP at the same dosage, and docetaxel (T) was only introduced from cycle 2 of IC to see what is the role of T in the observed side effect.
  • Two DLTs were observed among this second cohort of subjects: one pt presented a grade 2 renal toxicity, grade 3 diarrhea and dehydration and a second pt presented a grade 3 anorexia and grade 3 stomatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Palencár D, Hedera J, Fedeles J, Dolezal J, Pind'ák D: Reconstruction of a circular defect of the hypopharynx and cervical part of esophagus by a free jejunal flap (case report). Acta Chir Plast; 2005;47(2):35-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of a circular defect of the hypopharynx and cervical part of esophagus by a free jejunal flap (case report).
  • Reconstruction of the hypopharynx and esophagus is desirable in cases of congenital deformities, corrosive injuries, or defects after tumor resections.
  • Free flap allows for easier reconstruction of head and neck defects.
  • In this article, the authors present a case of complete hypopharynx closure in an oncology patient with a larynx carcinoma.
  • The patient is a 60-year-old male diagnosed in 2002 with epidermoid carcinoma of larynx.
  • The patient underwent laser resection of the tumor followed by radiotherapy and chemotherapy.
  • In 2003 the patient underwent pharyngo - laryngectomy for relapse of the larynx carcinoma.
  • Postoperatively the patient developed pharyngo - cutaneous fistula, which was reconstructed at the otorhinolaryngology department by a muscle - cutaneous flap from the pectoralis major muscle.
  • During the course of healing the patient developed complete hypopharynx and cervical esophagus closure.
  • Free flap of jejunum was recommended.
  • On the second day after the surgery patient developed salivary fistula in the wound.
  • Free flap of the jejunum allowed for upper gastrointestinal tract reconstruction and allowed the patient to restart peroral intake.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharynx / surgery. Jejunum / transplantation. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Humans. Laser Therapy. Male. Postoperative Complications. Reconstructive Surgical Procedures. Salivary Gland Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035154.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


23. Oboón B, Zalba B, López C, Gutiérrez I, Villanueva B, González J: [Exoftalmos and palpebral ptosis in the immunocompromised patient]. An Med Interna; 2003 Jun;20(6):309-11
Genetic Alliance. consumer health - Ptosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Exoftalmos y ptosis palpebral en paciente inmunodeprimido.
  • The mucormycosis is an opportunistic mycosis which has a high rate of global mortality with a bad prognosis.
  • The present clinical case shows a patient attended in the Intensive Care Unit because of a breathing insufficiency secondary to a pneumonia.
  • Among his antecedents there is a larynx carcinoma totally remittent after chemo- and radiotherapy.
  • Having that evolution, it is implemented a treatment with liposomal amphotericin B and granulocyte colony-stimulating factors after an injury biopsy, whose posterior cultive shows growing of Mucor.
  • This kind of pathology must be initially suspected in all the patients with a neoplasia and its treatment must be early and agressive.
  • At the moment the diagnosis is suspected there is a great tissue destruction and for that reason the patients usually die in spite of the instauration of aggressive therapies
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Fatal Outcome. Humans. Immunocompromised Host. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Male. Malnutrition / complications. Malnutrition / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12848603.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Bogo D, de Matos MF, Honda NK, Pontes EC, Oguma PM, da Santos EC, de Carvalho JE, Nomizo A: In vitro antitumour activity of orsellinates. Z Naturforsch C; 2010 Jan-Feb;65(1-2):43-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the anticancer activity of lecanoric acid, a secondary metabolite of the lichen Parmotrema tinctorum, and its derivatives, orsellinates, obtained by structural modification.
  • A cytotoxicity assay was carried out in vitro with sulforhodamine B (SRB) using HEp-2 larynx carcinoma, MCF7 breast carcinoma, 786-0 kidney carcinoma, and B16-F10 murine melanoma cell lines, in addition to a normal (Vero) cell line in order to calculate the selectivity index of the compounds. n-Butyl orsellinate was the most active compound, with IC50 values (the concentration that inhibits 50% of growth) ranging from 7.2 to 14.0 microg/mL, against all the cell lines tested.
  • The compound was more active (IC50 = 11.4 microg/mL) against B16-F10 cells than was cisplatin (12.5 microg/mL).
  • Conversely, lecanoric acid and methyl orsellinate were less active against all cell lines, having an IC50 value higher than 50 microg/mL.
  • Ethyl orsellinate was more active against HEp-2 than against MCF7, 786-0, or B16-F10 cells.
  • The same pattern was observed for n-propyl and n-butyl orsellinates. n-Pentyl orsellinate was less active than n-propyl or n-butyl orsellinates against HEp-2 cells.
  • The orsellinate activity increased with chain elongation (from methyl to n-butyl), a likely consequence of an increase in lipophilicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Resorcinols / therapeutic use. Salicylates / therapeutic use. Vero Cells / drug effects
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Cell Adhesion. Cell Line, Tumor. Cercopithecus aethiops. Female. History, Medieval. Humans. Melanoma, Experimental / drug therapy. Models, Molecular

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20355320.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Resorcinols; 0 / Salicylates; 11XLA0494B / orsellinic acid; 480-56-8 / lecanoric acid
  •  go-up   go-down


25. Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol; 2001 May;2(5):261-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
  • Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patients with advanced-stage head and neck cancer.
  • Here we review the results of both induction chemotherapy and chemoradiotherapy trials in patients with curable disease, and chemotherapy trials in patients with recurrent and metastatic disease, and we highlight current areas of investigation.
  • Compared with traditional treatment modalities, chemotherapy given on induction schedules to patients with advanced laryngeal cancer allows greater organ preservation without compromise to survival; when given concomitantly with radiotherapy to patients with resectable or unresectable advanced disease, chemotherapy again improves survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy, Combination. Humans. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Randomized Controlled Trials as Topic. Research. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905780.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 80
  •  go-up   go-down


26. Ferlito A, Silver CE, Rinaldo A, Smith RV: Surgical treatment of the neck in cancer of the larynx. ORL J Otorhinolaryngol Relat Spec; 2000 Jul-Aug;62(4):217-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of the neck in cancer of the larynx.
  • Current concepts in management of the clinically negative and clinically positive neck in laryngeal cancer are reviewed.
  • Immunohistochemistry or molecular analysis may detect metastatic involvement not apparent by light microscopy.
  • The surgeon should be aware of the relatively high incidence of micrometastases in patients with laryngeal cancer to establish optimal treatment approaches.
  • Elective treatment of the neck is recommended for supraglottic tumors staged T2 or higher, and glottic or subglottic tumors staged T3 or higher.
  • The neck may be treated electively by either surgery or irradiation, but irradiation is best reserved for cases where that modality is employed for the primary tumor.
  • Elective neck dissection provides important information for prognostic purposes and therapeutic decisions, by establishing the presence, number, location and nature of occult lymph node metastases.
  • The selective lateral neck dissection (levels II, III and IV), unilateral or bilateral, is the procedure of choice for elective treatment.
  • Paratracheal nodes (level VI) should be dissected in cases of advanced glottic and subglottic cancer.
  • Sentinel lymph node biopsy may fail to detect tumor on frozen section examination or may not reveal 'skip' metastases.
  • More advanced disease has been treated in this manner often in association with adjuvant chemotherapy and/or irradiation.
  • While the benefit of adjuvant treatment is difficult to assess, it appears most useful in cases with extranodal spread of disease, a factor associated with the worst prognosis.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Lymph Node Excision. Neck / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10859523.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 114
  •  go-up   go-down


27. Ohba S, Fujimori M, Ito S, Matsumoto F, Hata M, Takayanagi H, Wada R, Ikeda K: A case report of metastasizing myoepithelial carcinoma of the parotid gland arising in a recurrent pleomorphic adenoma. Auris Nasus Larynx; 2009 Feb;36(1):123-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of metastasizing myoepithelial carcinoma of the parotid gland arising in a recurrent pleomorphic adenoma.
  • Myoepithelial carcinoma, arising in a recurrent or in a pre-existing pleomorphic adenoma of the parotid gland is an extremely rare cancer.
  • We herein report the case of myoepithelial carcinoma occurring in a recurrent pleomorphic adenoma, which showed a high metastatic potential.
  • A total parotidectomy and a thoracoscopic biopsy of the lung lesion revealed both lesions to be myoepithelial carcinoma.
  • The patient died about 12 months later despite undergoing intensive chemotherapy.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lung Neoplasms / secondary. Myoepithelioma / pathology. Neoplasms, Second Primary / pathology. Parotid Neoplasms / pathology. Solitary Pulmonary Nodule / secondary
  • [MeSH-minor] Humans. Male. Middle Aged. Parotid Gland / surgery

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650039.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Gagnon PJ, Galderisi C, Page BR, Holland JM: Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx. Head Neck; 2009 Jun;31(6):829-32
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
  • BACKGROUND: Angiosarcoma arising after radiation is described in breast cancer but occurs elsewhere.
  • METHODS: This is a case of angiosarcoma developing 5 years after curative therapy for T3N0 squamous cell carcinoma of the supraglottic larynx.
  • Therapy consisted of 3 cycles of induction cisplatin/5-fluorouracil chemotherapy followed by radiotherapy.
  • Examination showed a 7-cm mass and biopsy revealed angiosarcoma.
  • CT scans assessed the local extent of the tumor and ruled out metastatic disease prior to initiating therapy.
  • RESULTS: Therapy consisted of 4 cycles of paclitaxel chemotherapy.
  • At completion, examination revealed mild induration of the neck with near-complete resolution of the mass.
  • CONCLUSION: This rare therapy-related second malignancy developed after curative larynx-preserving treatment.
  • Paclitaxel was an effective therapy in this setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / therapy. Hemangiosarcoma / etiology. Laryngeal Neoplasms / therapy. Radiotherapy, High-Energy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18853452.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Al-Zahid S, Singh V: Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma. J Laryngol Otol; 2010 Jan;124(1):90-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculous cervical lymphadenitis in a patient with laryngeal carcinoma.
  • OBJECTIVE: We report an extremely rare presentation of concomitant tuberculous cervical lymphadenitis in a patient with carcinoma of the larynx.
  • CASE REPORT: A 66-year-old man presented with a nine-month history of hoarseness.
  • Biopsy of the vocal fold lesion revealed invasive squamous cell carcinoma.
  • The patient was treated with radiotherapy to the larynx and concomitant anti-tuberculosis chemotherapy.
  • Five months following treatment, there was no sign of laryngeal cancer recurrence; however, the patient continued to have a productive cough and night sweats.
  • CONCLUSION: To our knowledge, this is the first report of a laryngeal carcinoma with concurrent tuberculous cervical lymphadenitis.
  • In the face of an unhelpful fine needle aspiration cytology examination, an assumption of metastatic neck disease could have been made.
  • Subsequent surgical and/or oncological intervention would have been highly inappropriate, with potentially catastrophic effects.
  • This case highlights the importance of proper diagnosis, and emphasises the fact that tuberculosis should always be borne in mind in the differential diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Laryngeal Neoplasms / complications. Tuberculosis, Lymph Node / complications
  • [MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Biopsy. Humans. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Treatment Outcome. Vocal Cords / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646297.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


30. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • These patients include a mixture of presentations including primary, recurrent, and metastatic lesions.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Walvekar RR, Pantvaidya GH, Desai SB, Chaukar DA, D'Cruz AK: Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report. Auris Nasus Larynx; 2006 Dec;33(4):493-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report.
  • We present a report of a patient with a treated and controlled pyriform sinus cancer who presented with complaints of dysuria, 8 months after completion of treatment.
  • Cystoscopy revealed a bladder mass and biopsy confirmed it to be a metastatic squamous cell carcinoma.
  • On further investigation, the patient was found to have disseminated disease for which chemotherapy was instituted.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Cystoscopy. Fatal Outcome. Humans. Male. Neck Dissection. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinus cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920307.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Calais G: [Docetaxel and squamous cell carcinoma of the head and neck]. Bull Cancer; 2004 Feb;91(2):167-71
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Docetaxel and squamous cell carcinoma of the head and neck].
  • [Transliterated title] Docetaxel et carcinomes de la tête et du cou.
  • Chemotherapy in head and neck carcinoma is used as palliative treatment but also as induction treatment or combined treatment with concurrent radiation therapy.
  • Docetaxel is an active drug for treating head and neck carcinoma.
  • For patients with recurrent or metastatic disease, docetaxel could be used either as a second line chemotherapy or a first line for patients who received previously platinum or 5FU.
  • In combination with platinum and 5FU, used as induction chemotherapy the TPF regimen is a very active treatment with an overall response rate of 85 to 90% with a manageable acute toxicity rate.
  • This approach is under investigation in terms of ability to obtain more larynx preservation compared to the standard approach with platinum and 5FU.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Remission Induction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright John Libbey Eurotext 2003.
  • (PMID = 15047456.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; U3P01618RT / Fluorouracil
  • [Number-of-references] 21
  •  go-up   go-down


33. Watanabe N, Inohara H, Akahani S, Yamamoto Y, Moriwaki K, Kubo T: Synchronous squamous cell carcinoma and malignant lymphoma in the head and neck region. Auris Nasus Larynx; 2007 Jun;34(2):273-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous squamous cell carcinoma and malignant lymphoma in the head and neck region.
  • Synchronous malignancy of squamous cell carcinoma (SCC) and malignant lymphoma (ML) in the head and neck region is extremely rare.
  • Here, we report the case of a 57-year-old man with a right-sided neck mass; he was referred to our hospital in September 2001.
  • The metastatic lymph nodes showed poor response to the radiotherapy, and the patient was surgically salvaged by modified radical neck dissection.
  • Although systemic chemotherapy against ML was scheduled, he refused the treatment and died of disseminated ML.
  • It is essential to determine the lesion that should be given priority treatment in case of double primary malignancies; this can be facilitated by determining the prognosis of each malignancy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Magnetic Resonance Imaging. Nasopharyngeal Neoplasms / diagnosis. Oropharyngeal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Disease Progression. Endoscopy. Follow-Up Studies. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949236.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Pignon JP, Bourhis J, Domenge C, Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet; 2000 Mar 18;355(9208):949-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.
  • BACKGROUND: Despite more than 70 randomised trials, the effect of chemotherapy on non-metastatic head and neck squamous-cell carcinoma remains uncertain.
  • We did three meta-analyses of the impact of survival on chemotherapy added to locoregional treatment.
  • We included patients with carcinoma of the oropharynx, oral cavity, larynx, or hypopharynx.
  • FINDINGS: The main meta-analysis of 63 trials (10,741 patients) of locoregional treatment with or without chemotherapy yielded a pooled hazard ratio of death of 0.90 (95% CI 0.85-0.94, p<0.0001), corresponding to an absolute survival benefit of 4% at 2 and 5 years in favour of chemotherapy.
  • There was no significant benefit associated with adjuvant or neoadjuvant chemotherapy.
  • Chemotherapy given concomitantly to radiotherapy gave significant benefits, but heterogeneity of the results prohibits firm conclusions.
  • Meta-analysis of six trials (861 patients) comparing neoadjuvant chemotherapy plus radiotherapy with concomitant or alternating radiochemotherapy yielded a hazard ratio of 0.91 (0.79-1.06) in favour of concomitant or alternating radiochemotherapy.
  • Three larynx-preservation trials (602 patients) compared radical surgery plus radiotherapy with neoadjuvant chemotherapy plus radiotherapy in responders or radical surgery and radiotherapy in non-responders.
  • The hazard ratio of death in the chemotherapy arm as compared with the control arm was 1.19 (0.97-1.46).
  • INTERPRETATION: Because the main meta-analysis showed only a small significant survival benefit in favour of chemotherapy, the routine use of chemotherapy is debatable.
  • For larynx preservation, the non-significant negative effect of chemotherapy in the organ-preservation strategy indicates that this procedure must remain investigational.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / therapy. Proportional Hazards Models. Randomized Controlled Trials as Topic. Treatment Outcome


35. Bourhis J, Lefebvre JL, Vermorken JB: Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options? Eur J Cancer; 2010 Jul;46(11):1979-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
  • The treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has evolved in recent years as a consequence of a better understanding of the potential benefits associated with altered radiation fractionation regimens, concurrently administered chemotherapy and radiotherapy (chemoradiotherapy) and induction chemotherapy.
  • Concurrent chemoradiotherapy is a treatment option for technically resectable disease, where functional morbidity precludes the use of surgery.
  • Induction chemotherapy followed by radiotherapy may also be used in this setting, and has been validated for larynx preservation.
  • Concurrent chemoradiotherapy is a standard treatment approach for medically fit patients with locoregionally advanced unresectable disease.
  • However, the toxicity burden of additional chemotherapy in both the concurrent chemoradiotherapy and induction chemotherapy settings can have implications for treatment compliance and may impede the administration of chemotherapy and/or radiotherapy to schedule.
  • The epidermal growth factor receptor (EGFR)-targeted IgG1 monoclonal antibody, cetuximab (Erbitux), has shown significant clinical benefits in the treatment of both locoregionally advanced and recurrent and/or metastatic SCCHN.
  • A phase III study in locoregionally advanced disease demonstrated significant improvements in locoregional control and progression-free and overall survival with cetuximab plus radiotherapy compared with radiotherapy alone, and overall survival benefits were maintained at 5 years.
  • Taken together, these data support an important role for cetuximab in the treatment paradigm for locoregionally advanced SCCHN.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Humans. Papillomavirus Infections / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20561781.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  •  go-up   go-down


36. Burns P, Sheahan P, Doody J, Kinsella J: Clavicular osteomyelitis: a rare complication of head and neck cancer surgery. Head Neck; 2008 Aug;30(8):1124-7
MedlinePlus Health Information. consumer health - E. Coli Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clavicular osteomyelitis: a rare complication of head and neck cancer surgery.
  • BACKGROUND: We report the 10th case in the English-language literature describing clavicular osteomyelitis that presented after radical treatment for laryngeal carcinoma and discuss the pertinent diagnostic and therapeutic measures.
  • The differential diagnosis included tumor recurrence, metastatic bone disease, and postradiotherapy complications.
  • METHODS AND RESULTS: A 45-year-old man who was a heavy smoker and known drug abuser presented with acute airway compromise and was diagnosed with squamous cell carcinoma involving the glottis and subglottis.
  • On follow-up 1 year later, the patient was seen with left stomal dehiscence and a large area of cellulitis extending across the left clavicle and down to the axilla.
  • Biopsy showed no evidence of tumor.
  • After aggressive treatment, the patient remains disease free.
  • Aggressive surgical debridement and antibiotic therapy remains the mainstay of treatment.
  • Prompt diagnosis and treatment are mandatory due to the potential life-threatening complications associated with the condition.
  • [MeSH-major] Clavicle / microbiology. Escherichia coli Infections / diagnosis. Osteomyelitis / etiology. Postoperative Complications
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Humans. Laryngeal Neoplasms / therapy. Laryngectomy. Male. Middle Aged. Neck Dissection. Radiotherapy, Adjuvant. Staphylococcal Infections / diagnosis. Surgical Stomas. Surgical Wound Dehiscence / microbiology. Surgical Wound Dehiscence / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18228522.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T: Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol; 2007 Sep;43(8):749-56
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
  • Induction chemotherapy or concomitant chemoradiotherapy has been used increasingly to improve survival, organ preservation and function in patients with head and neck cancer (HNC).
  • Therefore, reliable chemosensitivity assays are needed to accurately predict the response to chemotherapy and guide the selection and treatment of patients with HNC.
  • The main purpose of this study was to examine the optimal drug concentrations for evaluating in vitro chemosensitivity using the histoculture drug response assay (HDRA).
  • The tested tumor specimens included 7 from oral cavities (14.3%), 12 from oropharynx (24.5%), 10 hypopharynx (20.4%), 3 larynx (6.1%), 5 sinonasal (10.2%), 2 salivary glands (4.1%), and 10 from metastatic lymph nodes (20.4%), respectively.
  • Histopathologic types of all 49 specimens were squamous cell carcinoma.
  • We investigated the optimal drug concentrations in HDRA searching at doses of 4-100 microg/ml for cisplatin and 60-1500 microg/ml for 5-FU.
  • As for cisplatin sensitivity in vitro, the 50% cut-off inhibition index (I.I.) was found to have a significant association with the clinical response to chemotherapy, with an accurate prediction rate of 77.8%.
  • The HDRA shows a predictive value for chemosensitivity in HNC patients using the optimal drug concentration cut-off with this site specificity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Drug Screening Assays, Antitumor / methods. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Fluorouracil / pharmacology. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112769.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


38. Relic A, Scheich M, Stapf J, Voelter C, Hoppe F, Hagen R, Pfreundner L: Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas. Eur Arch Otorhinolaryngol; 2009 Nov;266(11):1799-805
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after induction chemotherapy with paclitaxel/cisplatin and primary radiotherapy for advanced laryngeal and hypopharyngeal carcinomas.
  • Induction chemotherapy followed by primary radiotherapy in responders is considered an alternative to surgery for advanced cancer of the larynx and hypopharynx (LHC).
  • Comparison of therapeutic approaches is challenging and must respect oncological and functional outcome as well as quality of life during and after treatment.
  • One aspect of primary radiochemotherapy is the option of salvage surgery in case of residual tumor.
  • All patients undergoing induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy from 01/96 to 07/05 were included.
  • Complete tumor removal, perioperative morbidity, and overall survival were analyzed in a retrospective study.
  • 28 out of 134 patients underwent salvage surgery after primary treatment with induction chemotherapy and radiotherapy for advanced LHC.
  • 15 patients had laryngectomy (LE) with neck dissection (ND), while 1 patient had lasersurgical partial laryngeal resection with ND for local recurrences.
  • In 56% of the cases, tumor removal turned out to be microscopically incomplete.
  • Eight out of 12 patients who underwent salvage ND because of suspicious lymph nodes (66%) were free of vital tumor.
  • When metastatic disease was present in the neck (4/12), recurrences occurred in 75% during postoperative follow-up.
  • Only 2 out of 20 patients undergoing surgery for histologically proven recurrence after radiochemotherapy (10%) are actually tumor-free and alive after a mean observation time of 43.9 months.
  • ND for suspicious persistent nodal disease after radiochemotherapy can be an over-treatment.
  • In the light of our results, unfavourable outcome after salvage surgery must be pointed out when initially informing patients about different therapeutic options for advanced LHC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Retrospective Studies. Taxoids / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1992 Aug;102(8):934-9 [1495357.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Sep;95(2):213-8 [3108762.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5 [9708712.001]
  • [Cites] Strahlenther Onkol. 2002 Jul;178(7):363-8 [12163990.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31 [16702569.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Feb;121(2):162-5 [7840923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Dec;126(12):1473-7 [11115285.001]
  • [Cites] Head Neck. 2007 Aug;29(8):715-9 [17274056.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] Am J Otolaryngol. 2005 Nov-Dec;26(6):388-92 [16275407.001]
  • [Cites] Head Neck. 2002 Aug;24(8):759-65 [12203801.001]
  • [Cites] Acta Otolaryngol. 2005 Jan;125(1):91-5 [15799582.001]
  • [Cites] J Laryngol Otol. 1993 Feb;107(2):130-2 [8496645.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1297-301 [7037159.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):662-4 [8988672.001]
  • [Cites] Acta Oncol. 2002;41(1):69-76 [11990522.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):441-8 [17180512.001]
  • [Cites] J Laryngol Otol. 1972 Aug;86(8):785-93 [5044285.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):673-8 [3338032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1418-23 [15050318.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Laryngoscope. 1980 Jun;90(6 Pt 1):930-45 [7382709.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):855-8 [16735902.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):892-8 [10828805.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(11):1225-8 [17050318.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jul;131(1):61-8 [15243559.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Dec;104(12):936-41 [7492064.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1887-93 [2414254.001]
  • [Cites] Cancer. 1982 Dec 15;50(12 ):2795-801 [6182982.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1864-6 [17003711.001]
  • [Cites] J Laryngol Otol. 1984 Sep;98(9):905-7 [6481227.001]
  • [Cites] Head Neck. 1997 Mar;19(2):116-20 [9059868.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):350-6 [2759253.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Apr;112(4):437-9 [3484960.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):245-9 [2325423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1975 Nov-Dec;84(6):833-40 [1053455.001]
  • [Cites] Head Neck. 2005 Aug;27(8):653-8 [16035097.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2006 Jun;115(6):419-24 [16805372.001]
  • [Cites] Radiother Oncol. 1984 Jun;2(1):31-6 [6505273.001]
  • [Cites] Laryngoscope. 1995 Jan;105(1):97-101 [7837923.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):420-4 [9109791.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2000 Apr;25(2):146-52 [10816221.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Head Neck. 2005 Feb;27(2):101-7 [15529321.001]
  • (PMID = 19288123.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


39. Rajendran ES: Homeopathy as a supportive therapy in cancer. Homeopathy; 2004 Apr;93(2):99-102
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeopathy as a supportive therapy in cancer.
  • Three cases of cancer in which homeopathic treatment was used in a complementary role are described: A 64-year-old male with metastatic adenocarcinoma of the rectum.
  • A 77-year-old female with terminal squamous cell carcinoma of the cheek previously treated with radiotherapy.
  • There was intense pain not relieved by available treatment.
  • A 70-year-old male with carcinoma of the larynx.
  • He had been receiving homeopathic treatment after the diagnosis because of his faith in it.
  • He was advised to have surgery, radiation and chemotherapy, which he underwent immediately.
  • This treatment was followed by homeopathic constitutional treatment.
  • The patient was symptom-free at 3 year follow-up.
  • [MeSH-major] Homeopathy. Neoplasms / therapy. Pain Management
  • [MeSH-minor] Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Facial Neoplasms / therapy. Female. Humans. Laryngeal Neoplasms / therapy. Male. Pain / etiology. Rectal Neoplasms / therapy. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139095.001).
  • [ISSN] 1475-4916
  • [Journal-full-title] Homeopathy : the journal of the Faculty of Homeopathy
  • [ISO-abbreviation] Homeopathy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


40. Righini CA, Bettega G, Lequeux T, Chaffanjeon P, Lebeau J, Reyt E: Use of tubed gastro-omental free flap for hypopharynx and cervical esophagus reconstruction after total laryngo-pharyngectomy. Eur Arch Otorhinolaryngol; 2005 May;262(5):362-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of tubed gastro-omental free flap for hypopharynx and cervical esophagus reconstruction after total laryngo-pharyngectomy.
  • In case of total laryngo-pharyngectomy (TLP), replacement of the pharyngoesophageal segment is more often done with jejunal flap; however, in some cases, this flap doesn't represent the best surgical technique of reconstruction.
  • The tubed gastro-omental free flap (TGO) offers an alternative procedure in selective cases.
  • Five patients had previously received systemic chemotherapy and external irradiation at curative doses, and three had undergone previous surgery.
  • Four patients died of loco-regional tumor evolution or distant metastatic disease.
  • The TGO offers a safe method of reconstructing the pharyngoesophageal segment in a surgical field compromised of previous multimodal therapy.
  • [MeSH-major] Esophagus / surgery. Hypopharynx / surgery. Laryngectomy. Pharyngectomy. Surgical Flaps
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / surgery. Cutaneous Fistula / etiology. Cutaneous Fistula / surgery. Esophageal Neoplasms / surgery. Humans. Larynx / surgery. Male. Middle Aged. Omentum / surgery. Pharyngeal Neoplasms / surgery. Reconstructive Surgical Procedures. Retrospective Studies. Stomach / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Plast Surg. 1992 Oct;19(4):819-31 [1339638.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 Jan-Feb;96(1 Pt 1):15-21 [3813380.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):847-53 [11448362.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):491-3 [7977982.001]
  • [Cites] Head Neck. 1994 Mar-Apr;16(2):149-54 [8021134.001]
  • [Cites] Neth J Surg. 1991 Oct;43(5):145-9 [1787897.001]
  • [Cites] Head Neck. 1997 Jan;19(1):68-71 [9030949.001]
  • [Cites] Ann Surg. 1961 Jul;154:103-6 [13714148.001]
  • [Cites] Plast Reconstr Surg. 1994 Aug;94(2):277-84; discussion 285-7 [8041818.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Dec;39(6):715-24 [7661553.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):213-8 [7782205.001]
  • [Cites] Plast Reconstr Surg. 1990 Nov;86(5):905-9 [2236315.001]
  • (PMID = 15378313.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


41. Erisen LM, Coskun H, Ozuysal S, Basut O, Onart S, Hizalan I, Tezel I: Basaloid squamous cell carcinoma of the larynx: a report of four new cases. Laryngoscope; 2004 Jul;114(7):1179-83
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the larynx: a report of four new cases.
  • OBJECTIVES: This study is designed to report the clinical and pathologic features and outcome of cases of basaloid squamous cell carcinoma (BSCC) of the larynx treated in our clinic.
  • METHODS: Four cases of BSCC of the larynx were treated in our department.
  • Histopathologic slides were reevaluated to confirm the diagnosis.
  • RESULTS: All patients were male (mean 57), with supraglottic or transglottic larynx tumors.
  • Initial diagnosis was invasive squamous cell carcinoma in 3 patients and BSCC in one patient.
  • Three patients received adjuvant postoperative radiotherapy, and 2 of them also received additional chemotherapy.
  • Patients with stage-IV disease were found to have 4 and 27 metastatic lymph nodes on histopathologic examination and died because of distant metastases at 11 and 14 months, respectively.
  • Patients with stage-II disease did not have cervical metastasis on histopathologic examination and were alive and free of disease at 52 and 72 months respectively.
  • CONCLUSION: In contrast with the literature reporting the tendency of more aggressive clinical behavior of the BSCC, we can say that BSCC has a behavior similar to conventional squamous cell carcinoma based on our 4 cases.
  • [MeSH-major] Carcinoma, Basosquamous / therapy. Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neck Dissection. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15235344.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Hoshikawa H, Mitani T, Nishiyama Y, Yamamoto Y, Ohkawa M, Mori N: Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. Auris Nasus Larynx; 2009 Apr;36(2):192-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET.
  • OBJECTIVE: The purpose of this study was to detect early stage recurrence or a residual tumor after chemoradiotherapy by FDG-PET.
  • METHODS: A total of 51 head and neck cancer lesions in 27 patients were examined-including primary sites and metastatic lymph nodes.
  • The therapeutic effects were evaluated by visual inspection, pre-treatment SUV, post-treatment SUV and % change in SUV.
  • RESULTS: No local recurrence was observed in 37 of the lesions, while recurrence or a residual tumor was observed in the other 14 lesions after therapy.
  • A significant difference was found between the two groups regarding the post-treatment SUV and the % change in SUV.
  • Taking the post-treatment SUV of 3 and the % change of 60 as a cut-off value, a significant difference was thus found between the recurrence cases and non-recurrence cases.
  • When all lesions were divided into two groups-including the post-treatment SUV>3 and the % change in the SUV<60 group, and the post-treatment SUV<3 or the % change in SUV>60 group, the overall accuracy was 88.2% (45/51).
  • Therefore, it is more useful to predict the prognosis after chemoradiotherapy by a combined analysis of the post-treatment SUV and the % change in SUV.
  • According to the post-treatment PET period, namely, within 4 weeks and from 5 to 15 weeks after treatment, the accuracy was 85.7% (24/28) and 91.3% (21/23), respectively (p=0.5385).
  • CONCLUSION: The results suggest that it may be possible to predict the recurrence even at 4 weeks after treatment.
  • Therefore, the use of a semi-quantitative analysis of FDG-PET between the pre-treatment and post-treatment findings is thus considered to be helpful in choosing the optimal therapy and for making an accurate prognosis.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Image Processing, Computer-Assisted. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm, Residual / radionuclide imaging. Otorhinolaryngologic Neoplasms / drug therapy. Otorhinolaryngologic Neoplasms / radiotherapy. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18606510.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Marioni G, Blandamura S, Calgaro N, Ferraro SM, Stramare R, Staffieri A, De Filippis C: Distant muscular (gluteus maximus muscle) metastasis from laryngeal squamous cell carcinoma. Acta Otolaryngol; 2005 Jun;125(6):678-82
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant muscular (gluteus maximus muscle) metastasis from laryngeal squamous cell carcinoma.
  • Clinical evidence of non-lymphatic distant metastasis has been reported in approximately 10% of cases of head and neck squamous cell carcinoma (HNSCC).
  • A 65-year-old male underwent supraglottic laryngectomy and left modified neck dissection for a carcinoma of the laryngeal surface of the epiglottis extending to both false cords.
  • Eight months later the patient underwent right radical modified neck dissection for hypodermal metastatic disease involving the underlying (sternocleidomastoid) muscle.
  • Thirty-two months later, surgical excision of a lesion in the right gluteus maximus muscle was performed.
  • Histological study diagnosed a muscular metastasis with the same morphological aspect as the laryngeal carcinoma.
  • Although skeletal muscles represent approximately 50% of total body mass and receive a large proportion of total cardiac output, haematogenous metastases to skeletal muscle are extremely uncommon.
  • Treatment options, depending upon the clinical setting, include observation, radiotherapy, chemotherapy and excision; these approaches rarely alter the patient outcome.
  • [MeSH-major] Buttocks / pathology. Carcinoma, Squamous Cell / secondary. Laryngeal Neoplasms / pathology. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076722.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


44. Jia SS, Wang YY, Pei R, Sun J: [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Feb;40(2):103-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathological feature and management of occult lymphatic metastasis in supraglottic carcinoma].
  • OBJECTIVE: To study the pathologic feature and management methods of occult lymphatic metastasis in patients with supraglottic carcinoma.
  • (1) Supraglottic squamous cell carcinoma;.
  • (3) no preoperative radiotherapy and (or) chemotherapy.
  • The distribution of metastatic lymph nodes was 9 in level II, 1 in level III, no in level I.
  • N0 recurrence in larynx and (or) at the neck after dissection.
  • Two years survival rates was 86.7% (26/30) without tumor.
  • CONCLUSION: Occult metastasis rate of supraglottic carcinoma is as high as 30%.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Laryngeal Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429726.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


45. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in management of oral cancer--surgery.
  • Oral cancer is the sixth most common cancer worldwide, with a high prevalence in South Asia.
  • Tobacco and alcohol consumption remain the most dominant etiologic factors, however HPV has been recently implicated in oral cancer.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • Primary site, location, size, proximity to bone, and depth of infiltration are factors which influence a particular surgical approach.
  • Reconstruction of major surgical defects in the oral cavity requires use of a free flap.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • The fibula free flap remains the choice for mandibular reconstruction.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Thus, larynx preservation with concurrent chemoradiotherapy has become the standard of care for locally advanced carcinomas of the larynx or pharynx requiring total laryngectomy.
  • On the other hand, for early staged tumors of the larynx and pharynx, transoral laser microsurgery has become an effective means of local control of these lesions.
  • Surgery thus remains the mainstay of management of a majority of neoplasms arising in the head and neck area.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


46. Genden EM, Ferlito A, Silver CE, Jacobson AS, Werner JA, Suárez C, Leemans CR, Bradley PJ, Rinaldo A: Evolution of the management of laryngeal cancer. Oral Oncol; 2007 May;43(5):431-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of the management of laryngeal cancer.
  • The treatment of laryngeal cancer has evolved through several phases, starting with wide extirpative surgical resection, and evolving through an era of conservation surgery and, finally, planned treatment using modalities of irradiation, chemotherapy and surgery in various combinations.
  • Attempts to extirpate laryngeal cancer date to the nineteenth century, but only by the mid-twentieth century did advances in anesthesia, blood transfusion and antibiotics, make this surgery safe and reliable.
  • Techniques of partial laryngectomy by external approach developed in the second half of the twentieth century, and endoscopic use of the laser refined the concept and provided a new paradigm for surgical treatment, particularly for early lesions.
  • During most of this era, radiation was employed as an alternative method of treatment, with surgery reserved for salvage of radiation failure.
  • By the last decade of the twentieth century, and to the present time, the value of combined modality therapy, using planned combinations of irradiation, chemotherapy and surgery became the standard of care for advanced laryngeal cancer, permitting maximal laryngeal preservation with the highest attainable cure rates.
  • [MeSH-major] Laryngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Otorhinolaryngologic Surgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112771.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 93
  •  go-up   go-down


47. Li X, Yang C, Su Z, Song Y: [The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Sep;15(9):401-2, 404
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The correlation of multidrug resistance phenotype with clinical response to chemotherapy in laryngeal cancer].
  • OBJECTIVE: The correlation of multidrug resistance(MDR) phenotype with clinical response to chemotherapy was investigated in patients with laryngeal cancer.
  • METHOD: Tumor specimens prior to neoadjuvant chemotherapy from 36 cases of laryngeal cancer were collected for detection of P-glycoprotein (P-gp) with anti-Pgp monoclonal antibodies (JSB-I).
  • Immunohistochemical assays were used for P-gp detection on 5 microns thick frozen section.
  • Anti-Pgp monoclonal antibodies(JSB-I) as primary antibodies and goat anti-mouse IgG monoclonal antibodies as second antibodies were applied.
  • All patients received preoperative induction chemotherapy with a regimen of cisplatin, 5-fluorouracil and pingyangmycin.
  • Evaluation for tumor response was scored as follows: Response to chemotherapy was graded as good for complete response or partial response; as poor for stable disease or progressive disease.
  • CONCLUSION: These preliminary data suggest that a significant correlation between MDR phenotype, Pgp-mediated and chemotherapy resistance existed.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Laryngeal Neoplasms / drug therapy. P-Glycoprotein / analysis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12541888.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


48. Gao X, Fisher SG, Mohideen N, Emami B: Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys; 2003 Jun 1;56(2):427-35
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cancers in patients with laryngeal cancer: a population-based study.
  • BACKGROUND: Literature regarding incidence of site-specific second cancers after laryngeal cancer is limited.
  • Risk factors associated with second primaries are unknown.
  • METHODS: Second primaries after laryngeal cancer in the SEER database (1973-1996) were analyzed for incidence, relative risk compared with the general population, and potential risk factors, including radiotherapy.
  • Information on chemotherapy and tobacco smoking was not available in the SEER database.
  • RESULTS: Of 20,074 laryngeal cancer patients surviving at least 3 months, 3533 (17.6%) developed second cancers.
  • The cumulative risk of developing a second cancer was 26% at 10 years and 47% at 20 years.
  • Compared with age-adjusted, gender, and tumor-specific rates in the general population, laryngeal cancer patients had higher risks of second cancers overall (observed-to-expected ratio [O/E] = 1.68, 95% confidence interval [CI] = 1.58-1.79), head-and-neck (4.81 [4.31-5.58]), esophageal (3.99 [3.29-4.83]), and lung (3.56 [3.34-3.79]) cancer.
  • Advanced age at initial diagnosis was associated with increased risks of second cancers (p = 0.0001).
  • Radiotherapy was associated with increased risk of second cancers overall (relative risk [RR] = 1.10 [1.02-1.18], p = 0.012), especially second cancers of the lung (RR = 1.18, [1.05-1.33], p = 0.006) and possibly second cancers of the head and neck (RR = 1.26, [0.99-1.60], p = 0.061).
  • Radiotherapy was associated with a 68% excess risk (RR = 1.68, [1.16-2.43], p = 0.007) of developing a second head-and-neck cancer in patients who survived more than 5 years.
  • Second primary was associated with a poor survival (p = 0.0001).
  • CONCLUSIONS: Second cancers after laryngeal cancer are common, especially for long-term survivors.
  • Radiotherapy was associated with a small increased risk of developing second cancers overall and long-term risk of head-and-neck cancers.
  • This data should be interpreted with caution in light of the lack of information on chemotherapy and tobacco smoking in the SEER database.
  • Prevention and early detection are indicated.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Laryngeal Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Analysis of Variance. Confidence Intervals. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Risk. Survival Rate. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738317.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ishii K, Tashiro M, Hosono M, Fukuda H, Takada Y, Kondo S, Inoue Y, Iguchi H, Kusuki M, Yamane H: Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer. Acta Otolaryngol Suppl; 2004 Oct;(554):62-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
  • OBJECTIVE: This study was conducted to evaluate the efficacy and feasibility of our accelerated hyperfractionation with concomitant boost for stage II laryngeal cancer and stages III-IVb locally advanced head and neck cancer.
  • PATIENTS AND METHODS: From January 2000 to October 2001, eight patients with AJCC 1998 stage II laryngeal cancer and 11 patients with AJCC 1998 stages III-IVb locally advanced head and neck cancer underwent accelerated hyperfractionated radiation therapy.
  • For the stage II laryngeal cancer, radiation was delivered at a 2.0 Gy fraction a day, 5 fractions per week for the first 3 weeks, then 2 fractions (1.8 and 1.2 Gy) a day, 5 times a week for 2.5 weeks, with total dose of 69 Gy.
  • For stages III-IVb head and neck cancer, radiation was given at a 1.8 Gy fraction a day, 5 fractions per week for 6 weeks and a boost was added up to 70.5 Gy with 1.5 Gy as a second daily fraction during the last 2.2 weeks.
  • Among the patients, 16 (84%) received concomitant chemotherapy, mainly with low-dose carboplatin.
  • Acute toxicity based on RTOG criteria and tumor response at 1 month post-treatment were estimated as initial effects.
  • RESULTS: The overall response rate was 100% in patients with stage II laryngeal cancer and 91% in patients with stages III and IVb head and neck cancer.
  • Eighteen patients (95%) completed radiation therapy without interruption related to acute side effects, while one had prolongation of the treatment for more than 1 week because of neutropenia.
  • CONCLUSIONS: Our results demonstrated that accelerated hyperfractionation, mostly combined with concomitant chemotherapy, had a good overall response rate with acceptable toxicity in stage II laryngeal cancers and stages III-IVb head and neck tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Head and Neck Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15513514.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


50. Bonfils P, Trotoux J, Bassot V: Chemotherapy alone in laryngeal squamous cell carcinoma. J Laryngol Otol; 2007 Feb;121(2):143-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone in laryngeal squamous cell carcinoma.
  • AIMS: To evaluate the results of chemotherapy alone in patients with invasive squamous cell carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • METHODS: A comparison of results in a group of complete responders managed with a chemotherapy alone protocol, matched with those of an incomplete responder group managed with conventional modalities.
  • CONCLUSION: Our results confirm the fact that chemotherapy alone is a viable option in selected patients with carcinoma of the larynx who have achieved a complete clinical response after an induction chemotherapy protocol.
  • This therapeutic approach allows surgery and/or radiation therapy to be reserved for the management of metachronous second primary tumours.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005065.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We found a higher frequency of laryngeal tumour in group 2 (31 vs 17; p =.03).
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • Cancer was the first cause of death in both groups.
  • The overall survival of the population (108 patients) was 81.5% at one year, 49.6% at 3 years and 35.3% at 5 years with a median survival of 3 years.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • If confirmed, cost effectiveness of such complication must be integrated in larynx preservation protocols.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


52. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM: Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1087-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
  • PURPOSE: Pretreatment anemia is an adverse prognostic variable in squamous cell head-and-neck cancer (HNC) patients treated with radiotherapy (RT) alone.
  • Tumor hypoxia is an adverse parameter for treatment with RT alone or with RT and concurrent chemotherapy (CCT).
  • Tumor hypoxia is more prevalent in patients who present with pretreatment hemoglobin (Hgb) concentrations less than 13 g/dL.
  • This study was performed to evaluate whether pretreatment Hgb less than 13 g/dL was correlated with treatment outcome in patients with advanced HNC treated with a uniform regimen of RT/CCT.
  • METHODS AND MATERIALS: The study population consisted of patients with AJCC Stage III or IV, M0 HNC who were treated with 70 to 72.5 Gy accelerated hyperfractionated RT (1.25 Gy b.i.d.) and CCT consisting of 2 cycles of CDDP (12-20 mg/m(2)/d x 5 days) and continuous infusion 5-FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6.
  • These patients were enrolled on the experimental arm of a prospective randomized trial that compared this regimen to hyperfractionated irradiation alone from 1990 to 1996.
  • RT/CCT was delivered as standard therapy from 1996 to 2000.
  • The primary endpoint was failure-free survival (FFS).
  • Secondary endpoints included local-regional control and overall survival.
  • Primary tumor sites included oropharynx (43%), hypopharynx/larynx (36%), oral cavity (9%), and nasopharynx (6%).
  • Seventy-eight percent of the patients with Hgb 13 g/dL or higher and 92% of the patients with Hgb less than 13 g/dL had a primary tumor stage of T3 or T4 (p = 0.01).
  • The median (25-75%) decrease in Hgb during RT/CCT was 2.2 (1.3-3.1) g/dL, both in patients who failed and in those who remained disease-free.
  • The therapeutic effect of anemia correction is being evaluated in prospective trials.
  • [MeSH-major] Anemia / complications. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Hemoglobins / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752888.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer; 2010 Oct 15;116(20):4761-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
  • BACKGROUND: Patients with locally recurrent squamous cell cancer of the head and neck (SCCHN) are reported to have a poor prognosis and limited therapeutic options.
  • Both surgical resection and chemoradiotherapy are reported to result in median survivals of approximately 12 months.
  • This study reported the experience of the Dana-Farber Cancer Institute (DFCI) with IMRT-based chemoradiotherapy with or without surgery for locally recurrent SCCHN.
  • METHODS: The current study was a retrospective study of all patients treated at DFCI who were diagnosed with nonmetastatic second primary or recurrent SCCHN and who received reirradiation based on IMRT.
  • The primary endpoint was overall survival (OS), and secondary endpoints were locoregional (LRC) and distant control and acute and chronic toxicity.
  • Recurrent disease was treated in the oral cavity (4 patients), larynx/hypopharynx (13 patients), oropharynx (7 patients), nasopharynx (2 patients), and neck (9 patients).
  • The median radiation dose was 60 Gray (Gy), and all patients received concurrent chemotherapy.
  • Approximately 91% and 46%, respectively, of all patients developed at least 1 acute and late grade 3 toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retreatment. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20572036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Rivera F, Vega-Villegas ME, López-Brea MF, García-Castaño A, de Juan A, Collado A, Galdós P, Rubio A, del Valle A, Rama J, Sanz-Ortiz J: Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx. Laryngoscope; 2004 Jul;114(7):1163-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx.
  • OBJECTIVE: We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx.
  • The primary endpoint was clinical complete response (CR) to induction UFTVP, and secondary endpoints were long-term overall survival (OS) and survival with primary site preservation (SPP).
  • Main toxicity of UFTVP was G 3,4 neutropenia (73% of pts, 16% developed febrile neutropenia).
  • No pt died during treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Area Under Curve. Carboplatin / administration & dosage. Chi-Square Distribution. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Analysis. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15235341.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


55. Prades JM, Lallemant B, Garrel R, Reyt E, Righini C, Schmitt T, Remini N, Saban-Roche L, Timoshenko AP, Trombert B, Guerrier B: Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol; 2010;130(1):150-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
  • CONCLUSIONS: Conventional radiotherapy with concurrent cisplatin is significantly superior to induction cisplatin fluorouracil chemotherapy followed by radiotherapy in terms of laryngeal preservation in patients with T3 hypopharyngeal carcinoma.
  • Despite a high rate of laryngeal preservation no survival benefit was recorded in this selected population.
  • OBJECTIVES: To compare conventional radiotherapy with concurrent cisplatin to induction chemotherapy with cisplatin fluorouracil followed by conventional radiotherapy.
  • The primary end point was the preservation of the larynx.
  • The secondary end points included toxicity, causes of death, and survival rates.
  • PATIENTS AND METHODS: Seventy-one adult patients with previously untreated resectable T3 pyriform sinus squamous cell carcinoma were enrolled in the multicenter prospective randomized phase III trial.
  • RESULTS: The rates of laryngeal preservation at 2 years were 68% for the induction chemotherapy (IC) group and 92% for the chemoradiotherapy (CR) group (p = 0.016).
  • At 2 years, the event-free survival rates were 36% and 41% for the IC group and CR group, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Neoadjuvant Therapy. Pyriform Sinus
  • [MeSH-minor] Cause of Death. Combined Modality Therapy. Disease-Free Survival. Humans. Laryngectomy. Neoplasm Staging. Prognosis. Prospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449227.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Woo HJ, Bai CH, Kim YD, Song SY: Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child. Auris Nasus Larynx; 2009 Apr;36(2):244-6
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
  • Second malignant neoplasms (SMNs) have become a concern in survivors of childhood malignancy.
  • Although there are many reports describing SMN in patients treated for childhood cancer, salivary gland tumors rarely appear in these reports.
  • Radiotherapy is a well-known risk factor for the development of secondary salivary gland malignancies after the treatment of childhood cancer.
  • However, it is not well known whether chemotherapy itself treatment increases the risk of salivary gland malignancies.
  • We report a child case with mucoepidermoid carcinoma of the submandibular gland as a SMN after chemotherapy alone for acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Mucoepidermoid / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Neoplasms, Second Primary / chemically induced. Submandibular Gland Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Biopsy. Busulfan / adverse effects. Busulfan / therapeutic use. Child. Child, Preschool. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / adverse effects. Etoposide / therapeutic use. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Image Processing, Computer-Assisted. Male. Neck Dissection. Positron-Emission Tomography. Thioguanine / adverse effects. Thioguanine / therapeutic use. Tomography, X-Ray Computed. Transplantation Conditioning

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602781.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; FTK8U1GZNX / Thioguanine; G1LN9045DK / Busulfan; ZS7284E0ZP / Daunorubicin; DCTER protocol
  •  go-up   go-down


57. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst; 2009 Apr 1;101(7):498-506
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
  • BACKGROUND: Chemotherapy with cisplatin (P) and 5-fluorouracil (F) followed by radiotherapy in patients who respond to chemotherapy is an alternative to total laryngectomy for patients with locally advanced larynx and hypopharynx cancer.
  • The objective of this trial was to determine whether adding T to PF could increase the larynx preservation rate.
  • METHODS: Patients who had larynx and hypopharynx cancer that required total laryngectomy were randomly assigned to receive three cycles of TPF or PF.
  • Patients who responded to chemotherapy received radiotherapy with or without additional chemotherapy.
  • Patients who did not respond to chemotherapy underwent total laryngectomy followed by radiotherapy with or without additional chemotherapy.
  • The primary endpoint was 3-year larynx preservation rate.
  • Secondary endpoints included acute toxicities and overall response.
  • RESULTS: Baseline patient and tumor characteristics were well balanced between the TPF (n = 110) and PF (n = 103) groups.
  • With a median follow-up of 36 months, the 3-year actuarial larynx preservation rate was 70.3% with TPF vs 57.5% with PF (difference = 12.8%; P = .03).
  • CONCLUSIONS: In patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.
  • These results suggest that larynx preservation could be achieved for a higher proportion of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Laryngectomy / methods. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Taxoids / administration & dosage. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Aug 19;101(16):1157-8; author reply 1158 [19567423.001]
  • (PMID = 19318632.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, Taino R, Rossi F, Ardizzoia A, Oggionni M, Crispino S, Olmi P: Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori; 2006 Jan-Feb;92(1):41-54
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
  • AIMS AND BACKGROUND: To compare conventional fractionation (CF) radiation therapy (RT), arm A, versus a split-course accelerated hyperfractionated schedule (S-AHF), arm B, versus CFRT plus concomitant chemotherapy (CT), arm C, in terms of five-year survival and toxicity for squamous cell tumors of the oropharynx.
  • METHODS AND STUDY DESIGN: Between January 1993 and June 1998, 192 previously untreated patients with stage III and IV oropharyngeal carcinoma (excluding T1N1 and T2N1) were enrolled in a multicenter randomized phase III trial (ORO 93-01).
  • In arms A and C, 66 to 70 Gy in 33 to 35 fractions was administered five days a week for six and a half to seven weeks.
  • In arm B, the dose delivered was 64 to 67.2 Gy in two fractions of 1.6 Gy every day, five days a week, with a planned two-week split at 38.4 Gy.
  • In arm C the CT regimen consisted of three cycles of carboplatin and 5-fluorouracil (CBDCA 75 mg/m2 on days 1 to 4 and 5-FU 1000 mg/m2 i.v. on days 1 to 4 every 28 days).
  • Similarly, there was no statistically significant difference in terms of five-year relapse-free survival: 15% for arm A, 17% for arm B, and 36% for arm C.
  • There was a slight trend towards better five-year locoregional control (P = 0.07) for the combined arm: patients without locoregional relapse were 48% in arm C, 21% in arm A and 18% in arm B.
  • Locoregional control was significantly better when arm C was compared with arms A and B combined (P = 0.02; arm A+B 20%; arm C 48%).
  • Distant metastases were fairly balanced in the three arms (A: 14; B: 9; C: 11), with a tendency towards more frequent isolated distant metastasis development in arm C (8 of 11 [72%] versus 7 of 23 [30%] in arms A+B).
  • Five-year second-tumor-free survival was 85%.
  • The 13 second tumors were equally distributed and were mainly correlated with tobacco and alcohol consumption (five lung, two esophagus, two oral cavity, one larynx, one pancreas, one hepatocarcinoma, one myeloma).
  • Arm C showed slightly more G3+ late side effects involving subcutaneous tissues and mucosa, although significant late sequelae were relatively uncommon and the mucosal side effects were mostly transient.
  • The occurrence of persistent G3 xerostomia was comparable in the three treatment arms.
  • CONCLUSIONS: The results obtained with the combination of CT and RT compared with RT alone did not reach statistical significance, but combined treatment almost doubled the five-year overall survival, relapse-free survival and locoregional control rate.
  • Patients with advanced squamous cell carcinomas of the oropharynx who are medically suitable for the combined approach should be treated with a combination of radiotherapy and chemotherapy.
  • The occurrence of second tumors is relatively common in these patients and may contribute substantially to the causes of death.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carboplatin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Risk Factors. Salvage Therapy. Survival Analysis. Time Factors. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683383.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Bessède JP, Vinh D, Genet D, Khalifa N, Aubry K, Rhein B, Orsel S, Tubiana-Mathieu N, Clavère P: [Induction chemotherapy and laryngeal preservation in pharyngolaryngeal carcinomas. Study of a 124 serie's patients and patient's follow up with laryngeal preservation]. Rev Laryngol Otol Rhinol (Bord); 2004;125(2):81-8
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and laryngeal preservation in pharyngolaryngeal carcinomas. Study of a 124 serie's patients and patient's follow up with laryngeal preservation].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée dans les cancers du pharyngolarynx. Etude d'une série de 124 patients et suivi des patients en préservation laryngée.
  • OBJECTIVE: To try and determine the value of chemotherapy and its subsequent effect on laryngeal preservation in patients presenting with laryngeal and pharyngeal carcinomas.
  • The second group was treated with chemotherapy and subsequent salvage surgery and/or radiotherapy.
  • Their survival rates and laryngeal preservation rates were compared.
  • PATIENTS AND METHODS: From 251 patients the authors have retrospectively studied 124 patients with induction chemotherapy.
  • The survival rate has been compared with a control group of 127 patients who was treated by initial surgery and radiotherapy.
  • The survival for patients with a total clinical response following chemotherapy was 49.8% at 5 years.
  • Survival with no total clinical response following chemotherapy treated by secondary radiotherapy was 25.7% at 3 years.
  • The initial rate of laryngeal preservation is 32.2% but this rate fell to 22% after local recurrencies.
  • CONCLUSION: The group with total clinical response after induction chemotherapy with laryngeal preservation have a non significantly difference in their survival compared with the group initially treated by surgery and radiotherapy.
  • The rate of local recurrency of patients with laryngeal preservation is 32.5% and gives a finally rate of laryngeal preservation of 21%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Larynx / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462166.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


60. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • The main causes of death were metachronous second primary tumors (n = 27) and intercurrent disease (n = 21).
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • The 1-year and 5-year Kaplan-Meier local control estimates were 76.1% and 50.7%, respectively.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • CONCLUSIONS: For selected patients, EC may provide long-term, durable disease control.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


61. Agúndez JA, Gallardo L, Ledesma MC, Lozano L, Rodriguez-Lescure A, Pontes JC, Iglesias-Moreno MC, Poch J, Ladero JM, Benítez J: Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology; 2001;61(1):59-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients.
  • The cytochrome P450 CYP2D6 is a polymorphic drug-metabolizing enzyme that is involved in the metabolism of several drugs and xenobiotics.
  • Several independent studies indicate that the CYP2D6 metabolic status is a secondary factor in the risk of developing lung cancer, with individuals with high activity being at increased risk.
  • In order to establish whether the highest CYP2D6 enzyme activity is associated with an increased risk of cancer, we analyzed the frequency of CYP2D6 gene duplications and enzyme-inactivating mutations in 199 Caucasian patients with lung or larynx cancer and in 335 healthy controls.
  • A significantly increased frequency of carriers of the CYP2D6 gene duplication were found among lung and larynx cancer patients (13%), as compared with healthy controls (6.9%; p < 0.02).
  • The frequency of the mutated active CYP2D6*9 allele was increased in lung cancer patients (p < 0.01) but not in larynx cancer patients.
  • Global findings indicate that over 20% patients with lung or larynx cancer show CYP2D6 genotypes leading to ultrarapid metabolism or to the expression of an enzyme with altered kinetics (p < 0.01 vs. healthy controls).
  • This may influence the metabolism of CYP2D6 substrates, including antineoplastic drugs and opioid derivatives used for pain relief in cancer patients.
  • These patients would require higher doses than those considered as standard.
  • We conclude that dosages for CYP2D6 substrates should be adapted to lung and larynx cancer patients.
  • [MeSH-major] Cytochrome P-450 CYP2D6 / genetics. Genes, Duplicate. Laryngeal Neoplasms / enzymology. Laryngeal Neoplasms / genetics. Lung Neoplasms / enzymology. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Analgesics, Opioid / metabolism. Antineoplastic Agents / metabolism. Case-Control Studies. European Continental Ancestry Group / genetics. Female. Heterozygote. Humans. Male. Middle Aged. Pain / drug therapy. Pain / etiology. Polymorphism, Genetic. Prevalence. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11474250.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antineoplastic Agents; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  •  go-up   go-down


62. Laccourreye O, Veivers D, Bassot V, Ménard M, Brasnu D, Laccourreye H: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Apr;111(4):315-21; discussion 321-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure.
  • Based on an inception cohort of 35 patients with T1-3N0M0 squamous cell carcinoma of the true vocal cord who had a complete clinical response after a platinum-based induction chemotherapy regimen and a minimum of 3 years of follow-up, the current retrospective study documented the long-term results and consequences of local recurrence following the use of a platinum-based chemotherapy-alone regimen for cure.
  • During the years 1985 to 1996, 231 patients with invasive squamous cell carcinoma of the true vocal cord classified as T1-3N0M0 were managed at our department with a platinum-based induction chemotherapy regimen.
  • Thirty-five of the 77 patients with complete clinical response were managed at our institution with a platinum-based chemotherapy-alone regimen.
  • The statistical analysis of data on survival, local control, nodal control, distant metastasis, and metachronous second primary tumor incidence was based on the Kaplan-Meier product limit method.
  • Overall, the causes of death were intercurrent disease in 6 patients and metachronous second primary tumor in 4 patients.
  • The 3- and 5-year actuarial local control estimate was 64.8%.
  • Salvage treatment in patients with local recurrence yielded a 100% local control rate and laryngeal preservation rate.
  • The 3- and 5-year actuarial lymph node control estimate was 97.1%.
  • The 5- and 10-year actuarial estimates for patients with metachronous second primary tumor were 9.7% and 28.1%, respectively.
  • Although local recurrence was noted in almost a third of patients with complete clinical response who were managed with a platinum-based chemotherapy-alone regimen, it did not appear to be detrimental, as none of the patients who had local recurrence ultimately died from their disease or lost their larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local. Vocal Cords
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chi-Square Distribution. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2002 Sep;111(9):860 [12296346.001]
  • (PMID = 11991582.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


63. Habl G, Jensen AD, Potthoff K, Uhl M, Hof H, Hajda J, Simon C, Debus J, Krempien R, Münter MW: Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. BMC Cancer; 2010;10:651
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
  • BACKGROUND: Primary treatment of carcinoma of the oro-/hypopharynx or larynx may consist of combined platinum-containing chemoradiotherapy.
  • In order to improve clinical outcome (i.e. local control/overall survival), combined therapy is intensified by the addition of the EGFR inhibitor cetuximab (Erbitux®).
  • Radiation therapy (RT) is carried out as intensity-modulated RT (IMRT) to avoid higher grade acute and late toxicity by sparing of surrounding normal tissues.
  • METHODS/DESIGN: The REACH study is a prospective phase II study combining chemoradiotherapy with carboplatin/5-Fluorouracil (5-FU) and the monoclonal epidermal growth factor-receptor (EGFR) antibody cetuximab (Erbitux®) as intensity-modulated radiation therapy in patients with locally advanced squamous-cell carcinomas of oropharynx, hypopharynx or larynx.Patients receive weekly chemotherapy infusions in the 1st and 5th week of RT.
  • Additionally, cetuximab is administered weekly throughout the treatment course.
  • IMRT is delivered as in a classical concomitant boost concept (bid from fraction 16) to a total dose of 69,9 Gy.
  • DISCUSSION: Primary endpoint of the trial is local-regional control (LRC).
  • Disease-free survival, progression-free survival, overall survival, toxicity, proteomic and genomic analyses are secondary endpoints.
  • The aim is to explore the efficacy as well as the safety and feasibility of this combined radioimmunchemotherapy in order to improve the outcome of patients with advanced head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Otorhinolaryngologic Neoplasms / therapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Cetuximab. Chemotherapy, Adjuvant. Disease-Free Survival. Fluorouracil / administration & dosage. Germany. Humans. Hypopharyngeal Neoplasms / therapy. Kaplan-Meier Estimate. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy. Prospective Studies. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71 [11483325.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4637-42 [8402640.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):450-6 [16303861.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Feb;5(2):79-81 [17344795.001]
  • [Cites] N Engl J Med. 2007 Aug 2;357(5):514-5 [17671265.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1872-3; author reply 1873 [17978301.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):166-71 [18977050.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • (PMID = 21108850.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN87356938
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3001721
  •  go-up   go-down


64. Rivera F, Vega-Villegas ME, López-Brea M, Isla D, Mayorga M, Galdós P, Rubio A, Del Valle A, García-Reija F, García-Montesinos B, Rodríguez-Iglesias J, Mayordomo J, Rama J, Saiz-Bustillo R, Sanz-Ortiz J: Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). Cancer Chemother Pharmacol; 2008 Jul;62(2):253-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • OBJECTIVES: We conducted a multicentric randomized phase II trial comparing 5-FU continuous infusion (PF) and cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy (IC) in locally advanced squamous cell head and neck cancer (LA-SCHNC).
  • Primary objective was complete response (CR) to IC and overall survival (OS) was a secondary objective.
  • RESULTS: A total of 206 patients (pts) were included (PF/UFTVP: 99/107): oral cavity: 8%/10%, oropharynx: 20%/25%, hypopharynx: 17%/14%, larynx: 54%/50%.
  • IC with UFTVP was associated with a favourable OS in the Cox analysis (actuarial 5 year OS: 49% vs. 34%; HR: 0.67, 95% CI: 0.47-0.95, P: 0.03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease-Free Survival. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Tegafur / administration & dosage. Tegafur / adverse effects. Tegafur / therapeutic use. Uracil / administration & dosage. Uracil / adverse effects. Uracil / therapeutic use. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives. Vinblastine / therapeutic use


65. Slensky KA, Volk SW, Schwarz T, Duda L, Mauldin EA, Silverstein D: Acute severe hemorrhage secondary to arterial invasion in a dog with thyroid carcinoma. J Am Vet Med Assoc; 2003 Sep 1;223(5):649-53, 636
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute severe hemorrhage secondary to arterial invasion in a dog with thyroid carcinoma.
  • A 7-year-old spayed female Labrador Retriever was referred because of progressive swelling and bruising of the neck, hemothorax, a possible mediastinal mass, and stridor.
  • At the time of admission, the dog was recumbent, mentally dull, tachycardic, and hypothermic.
  • Fluid therapy with hydroxyethyl starch and a balanced electrolyte solution was administered because of presumed hypovolemic shock secondary to hemorrhage; multiple units of packed RBCs and fresh frozen plasma were also administered.
  • On the basis of the computed tomographic images, extensive subcutaneous, subfascial, and cranial mediastinal hemorrhage; hemothorax; prescapular lymphadenopathy; and a contrast-enhancing mass in the left cranioventral aspect of the neck were diagnosed.
  • During dissection of the clot, pulsatile bleeding was observed just caudal to and to the left of the larynx; ligation of the left common carotid artery resulted in immediate cessation of the pulsatile bleeding.
  • Further surgical exploration revealed a 2.5 x 2.5-cm mass adhered to the left common carotid artery at the level of the branching to the left cranial thyroid artery.
  • The mass was removed; the histologic diagnosis was thyroid carcinoma.
  • Three weeks after surgery, treatment with a combination of radiation and chemotherapy (doxorubicin and carboplatin) was begun.
  • Thirteen months after surgery, the dog continued to be free from clinical signs of disease.
  • [MeSH-major] Carcinoma / veterinary. Dog Diseases / pathology. Hemorrhage / veterinary. Thyroid Neoplasms / veterinary
  • [MeSH-minor] Animals. Blood Transfusion / veterinary. Carotid Artery, Common / pathology. Carotid Artery, Common / surgery. Combined Modality Therapy. Dogs. Erythrocyte Transfusion / veterinary. Female. Fluid Therapy / veterinary. Ligation. Neoplasm Invasiveness. Plasma. Shock / etiology. Shock / therapy. Shock / veterinary. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12959383.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Ansarin M, Planicka M, Rotundo S, Santoro L, Zurlo V, Maffini F, Alterio D, Cattaneo A, Chiesa F: Endoscopic carbon dioxide laser surgery for glottic cancer recurrence after radiotherapy: oncological results. Arch Otolaryngol Head Neck Surg; 2007 Dec;133(12):1193-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic carbon dioxide laser surgery for glottic cancer recurrence after radiotherapy: oncological results.
  • OBJECTIVE: To evaluate local control, organ preservation, and complications after endoscopic laser surgery for early recurrent glottic cancer after radiotherapy.
  • PATIENTS: The study, which was conducted between May 1999 and September 2005, included 37 consecutive patients (33 men and 4 women) with recurrent glottic cancer after radiotherapy.
  • Selection criteria were as follows: rcTis, rcT1, or rcT2 with subglottic or supraglottic involvement of less than 5 mm and no arytenoid invasion; adequate laryngeal exposure; no previous open surgery; no contraindications to general anesthesia; and signed consent.
  • INTERVENTIONS: Endoscopic laser surgery with curative intent using types III to V cordectomies according to the European Laryngological Association.
  • MAIN OUTCOME MEASURES: Five-year actuarial recurrence-free and overall survival, complications, and rate of laryngeal preservation.
  • New recurrences developed in 13 patients (35%): 11 were treated by total laryngectomy, 1 by supracricoid laryngectomy, and 1 by chemotherapy.
  • Three patients died of laryngeal cancer, 1 is alive with disease, and 1 died of a second cancer.
  • Five-year actuarial recurrence-free and overall survival rates were 58% and 86%, respectively.
  • The larynx was preserved in 26 patients (70%).
  • Laryngeal stenosis was the most common major complication (in 3 of 4 women and 1 of 33 men).
  • CONCLUSIONS: Endoscopic laser surgery is a safe and effective salvage procedure in selected cases involving glottic recurrence after radiotherapy.
  • Oncological results are satisfactory, and organ preservation can be achieved in a high proportion of cases; however, the risk of laryngeal stenosis is high in women.
  • [MeSH-major] Glottis. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngoscopy / methods. Laser Therapy / methods. Lasers, Gas. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086959.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Valentí V, López-Pousa A, Gonzalez Y, Farré N: Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature. J Craniofac Surg; 2005 May;16(3):452-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature.
  • The case of a 56-year-old man with osteogenic sarcoma of the mandible diagnosed 7 years after radiotherapy treatment of a laryngeal cancer is reported.
  • Surgery was the initial treatment.
  • The progress was poor after local and pulmonary relapse, without response to chemotherapy treatment.
  • The authors have found in the literature 30 cases of mandibular radiation-induced osteogenic sarcomas, most of them secondary to treatment of benign lesions, none of them secondary to treatment of a laryngeal cancer, as was seen in their case.
  • [MeSH-minor] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / radiotherapy. Fatal Outcome. Humans. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915114.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Janinis J, Papadakou M, Panagos G, Panousaki A, Georgoulias V, Hatzidaki D, Lefantzis D, Dokianakis G: Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol; 2001 Jun;24(3):227-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
  • The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).
  • Secondary endpoints included preliminary assessment of response.
  • Patients with locally advanced HNC, a World Health Organization performance status 0 to 2, and no prior history of chemotherapy or radiotherapy were included.
  • Treatment consisted of docetaxel 80 mg/m2 (1-hour infusion) on day 1, cisplatin 40 mg/m2 (1-hour infusion) on days 2 and 3, and 5-fluorouracil 1,000 mg/m2 (24-hour continuous infusion), on days 1 to 3, repeated every 28 days for a maximum of 4 cycles per patient.
  • All patients received granulocyte colony stimulating factors subcutaneously between days 4 and 9.
  • Radiation therapy (RT) to the primary tumor site and neck lymph nodes was planned within 5 weeks of the last cycle of chemotherapy.
  • The primary tumor site received 60 to 70 Gy.
  • The most common acute nonhematologic toxicities from DCF induction chemotherapy included alopecia, mucositis, peripheral sensory neuropathy, onycholysis, and asthenia.
  • Febrile neutropenia developed in two patients and grade IV diarrhea in one patient.
  • There were no treatment-related deaths.
  • The overall response rate (RR) after DCF induction chemotherapy was 90% (95% confidence interval [CI]: 76.8-103.1%).
  • After the completion of RT, the overall RR was 95% with a complete response rate of 73% (95% CI: 49.9-90.1%).
  • Organ preservation was achieved in eight patients with laryngeal cancer and one patient with base of tongue involvement.
  • After a median follow-up of 36 months (range: 5-43 months) the median disease-free and overall survival have not been reached yet.
  • Sequential chemoradiotherapy with DCF and growth factor support is feasible and very active, with durable responses in patients with locally advanced head and neck cancer.
  • Further evaluation of this modality is justified in the context of a clinical trial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Fluorouracil / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Taxoids
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404490.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Gallegos-Hernández JF: Partial surgery of the larynx: techniques and outcomes. Cir Cir; 2010 Sep-Oct;78(5):451-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial surgery of the larynx: techniques and outcomes.
  • BACKGROUND: in recent years preservation of the larynx has been one of the most studied subjects in the field of cervicofacial oncology and is the secondary target in the treatment of laryngeal cancer after locoregional control.
  • DISCUSSION: Treatment of cancers originating generally in the mucosa of the head and neck and in particular of the larynx has evolved greatly during the past 10 years.
  • Inclusion of induction chemotherapy and the association of concomitant chemotherapy/radiotherapy in the medical armamentarium has totally changed the therapeutic strategy for this neoplasm.
  • These techniques allow extirpation of the neoplastic portion of the organ, obtaining oncological treatment but preserving voice function, understandable phonation, normal swallowing function and breathing without tracheotomy.
  • It is important to determine whether these techniques are still useful in the present context of multidisciplinary treatment of laryngeal cancer.
  • The objective of this study is to demonstrate techniques, indications and errors to avoid in three surgical techniques considered useful to treat endolaryngeal tumors, preserving function.
  • CONCLUSIONS: in neoplasms of the larynx, in early as well as intermediate stages, these techniques offer excellent voice quality and suitable control specific to tumors located within the larynx.
  • In these patients, partial surgery offers adequate oncological control and a safe therapeutic and functional alternative.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laryngectomy / methods
  • [MeSH-minor] Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21219819.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


70. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The first is an 84-year-old male patient with cancer of the hypopharynx (T3N2aM1, stage IVc).
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


71. Dequanter D, Lothaire P: The role of salvage surgery in organ preservation strategies in advanced head and neck cancer. B-ENT; 2008;4(2):77-80
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of salvage surgery in organ preservation strategies in advanced head and neck cancer.
  • It is now established that head & neck squamous cell carcinomas represent a major group of tumours for which an improvement in the overall survival rate could be achieved by a multimodality approach.
  • Surgery as salvage treatment also continues to play an important role in organ preservation strategies in advanced head and neck cancer.
  • METHODS: Before the prospective randomised organ preservation trial conducted by the Department of Veterans Affairs Laryngeal Cancer Study Group demonstrating the benefits of induction chemotherapy, the standard of care for most advanced laryngeal/pharyngo-laryngeal carcinomas was total laryngectomy/pharyngo-laryngectomy and postoperative radiotherapy.
  • The new approach was also supported by a similar prospective trial from the EORTC Head & Neck Cooperative Group dealing with advanced hypopharyngeal squamous cell carcinomas.
  • Currently, advanced laryngeal/pharyngo-laryngeal carcinomas are treated with chemoradiotherapy but some patients will require a more complex salvage laryngectomy/pharyngo-laryngectomy.
  • RESULTS: In a first group of 44 patients treated with sequential chemotherapy and radiotherapy, median survival was 6.7 years.
  • Disease-free survival at 5 years was 50%.
  • 20/44 (50%) of patients retained their larynx.
  • Only 5 patients needed complex salvage surgery.
  • In the second group of 19 patients who received concomitant chemoradiotherapy, 78.9% of the patients retained their larynx.
  • CONCLUSION: CTx and RT is an effective strategy for organ preservation without compromising the survival of patients with locally advanced pharyngo-laryngeal carcinoma, keeping surgery for salvage.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Salvage Therapy / methods
  • [MeSH-minor] Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681202.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Belgium
  •  go-up   go-down


72. Nur DA, Oguz C, Kemal ET, Ferhat E, Sülen S, Emel A, Münir K, Ann CS, Mehmet S: Prognostic factors in early glottic carcinoma implications for treatment. Tumori; 2005 Mar-Apr;91(2):182-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in early glottic carcinoma implications for treatment.
  • AIM: In this study we aimed to determine the prognostic factors affecting local control (LC) in limited glottic carcinoma treated with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Between June 1991 and December 2001, 114 patients with early squamous-cell carcinoma of the glottis were treated with definitive RT at our institution.
  • A median dose of 66 Gy (50-70.2) was given over a median period of 46 days (20-60).
  • The prognostic parameters analyzed for LC were T classification, anterior commissure involvement, total RT dose, and overall treatment time.
  • RESULTS: Five-year local and regional control rates were 84.2% and 97.7%.
  • In 15 patients with local failure, salvage treatment consisted of partial laryngectomy in eight patients and total laryngectomy in five.
  • In one of the three patients with regional failure, salvage surgery was applied and the other two were given palliative chemotherapy because of unresectable disease.
  • Following salvage treatments, the ultimate five-year LC rate was 96.9% and the five-year larynx preservation rate was 91.1%.
  • Second primary cancer was diagnosed in 17 (14.9%) patients.
  • Only one patient developed distant metastases and two patients died of laryngeal cancer.
  • While T2 disease and anterior commissure involvement were found to be unfavorable prognostic factors significantly influencing LC in univariate analyses, only T2 disease remained independent in multivariate analysis.
  • CONCLUSION: In patients with early glottic carcinoma, T classification proved to be the only independent prognostic factor affecting LC after primary radiotherapy according to the results of this study.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948549.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Kasperts N, Slotman B, Leemans CR, Langendijk JA: A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol; 2005 Mar;41(3):225-43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review on re-irradiation for recurrent and second primary head and neck cancer.
  • The purpose of this paper is to review the results of studies regarding radiation as primary or adjuvant treatment modality for head and neck recurrences or second primary tumours (SPT) in previously irradiated areas, with emphasis on acute and late radiation induced morbidity, locoregional control and survival.
  • (1) re-irradiation for locoregional recurrent disease or SPT in the head and neck region, (2) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx, and (3) a minimum of 10 patients included in the study.
  • Studies were divided in four categories, including (1) external beam re-irradiation, (2) re-irradiation with brachytherapy, (3) re-irradiation in combination with chemotherapy and (4) postoperative re-irradiation.
  • Most studies were retrospective using heterogeneous treatment regimens and including heterogeneous groups of patients.
  • Overall survival, locoregional control and acute and late radiation-induced morbidity are reported.
  • High dose reirradiation as salvage treatment in case of recurrent or second primary head and neck cancer should be considered, particularly when salvage surgery is not feasible.
  • Although long term survivors are reported is some studies, the relatively high incidence of treatment-related morbidity emphasize the need for further optimisation in order to improve locoregional control and reduce the risk on late morbidity.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasms, Second Primary / radiotherapy
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Humans. Morbidity. Retreatment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2005 Oct;41(9):953-4 [15935725.001]
  • (PMID = 15743686.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


74. Dilkes MG, Benjamin E, Ovaisi S, Banerjee AS: Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol; 2003 Sep;117(9):713-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases.
  • The use of photodynamic therapy for the treatment of malignant and non-malignant conditions is increasing.
  • This paper demonstrates the efficacy of a second-generation photosensitizer, Foscan, in the primary treatment of a wide range of mucosal head and neck squamous cell carcinomas.
  • Tumours ranged in stage from T(1) to T(3).
  • A complete response to primary treatment was seen in 19/21 patients (90 per cent).
  • In laryngeal cancer recurrent after radical radiotherapy, one out of four patients treated obtained a complete response (25 per cent).
  • Six patients (24 per cent) required surgery after photodynamic therapy, for local recurrence or dysplasia.
  • Mean follow up was for 27.3 months (standard deviation 20.6 months).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561360.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


75. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, Takeuchi K, Kitamura K, Ichimura K, Ozawa K: Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther; 2003 Jan;10(1):51-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice.
  • The application of adeno-associated virus (AAV) vectors to cancers is limited by their low transduction efficiency.
  • Previously, we reported that gamma-ray enhanced the second-strand synthesis, leading to the improvement of the transgene expression, and cytocidal effect of the herpes simplex virus type-1 thymidine kinase (HSVtk) and ganciclovir (GCV) system.
  • First, the laryngeal cancer cell line (HEp-2) and HeLa were treated with AAVtk/GCV, the number of surviving cells was reduced as the concentration of GCV increased.
  • Furthermore, the 4 Gy irradiation enhanced the killing effects of AAVtk/GCV by four-fold on HeLa cells and 15-fold on HEp-2 cells.
  • These findings suggest that the combination of AAVtk/GCV system with radiotherapy is significantly effective in the treatment of cancers and may lead to reduction of the potential toxicity of both AAVtk/GCV and gamma-ray.
  • [MeSH-major] Antiviral Agents / administration & dosage. Ganciclovir / administration & dosage. Genetic Therapy / methods. Genetic Vectors / administration & dosage. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / therapy. Transduction, Genetic / methods
  • [MeSH-minor] Animals. Combined Modality Therapy. Dependovirus / genetics. Dose-Response Relationship, Drug. Gene Expression / radiation effects. HeLa Cells. Humans. Mice. Mice, Nude. Radiotherapy Dosage. Simplexvirus / enzymology. Thymidine Kinase / genetics. Transplantation, Heterologous. Tumor Cells, Cultured. beta-Galactosidase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525837.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; EC 3.2.1.23 / beta-Galactosidase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


76. Varghese BT, Sebastian P, Mathew A: Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol; 2009 Dec;129(12):1480-5
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study.
  • CONCLUSIONS: Compared with larynx cancers salvage rates are poorer for hypopharyngeal cancers and the role of primary surgery seems to be significantly higher and more decisive in overall survival (OS).
  • OBJECTIVE: To evaluate the survival and morbidity of patients treated by surgery for carcinoma of the larynx and hypopharynx according to site.
  • PATIENTS AND METHODS: All patients who had undergone laryngectomy at the Division of Surgical Oncology Regional Cancer Center (RCC) from June 1995 to December 2005 were included in the study, which retrospectively recorded the age and sex distribution, TNM stage, indication, type of laryngectomy and reconstructive option used.
  • The therapeutic outcome, disease-free survival (DFS), OS, voice preservation and postoperative voice rehabilitation were analysed.
  • RESULTS: Of a total of 167 cases, 123 (74%) had salvage surgery for failed chemoradiotherapy/radical radiotherapy and 44 (26%) had primary surgical treatment.
  • Five patients received platinum-based neoadjuvant chemotherapy and nine had postoperative chemotherapy.
  • There was a statistically significant survival difference between salvage and primary surgical cases among cancers of the larynx and hypopharynx.
  • One patient refused further surgical closure after a partially failed repair.
  • Fifty-six (34%) patients recurred locoregionally, 4 (2.3%) patients developed a second primary and 5 (2.9%) had distant metastasis.
  • Thirty patients were voice rehabilitated with an electronic larynx.
  • Seventeen patients had voice prosthesis insertion (6 primary and 10 secondary), 3 patients developed good oesophageal speech and voice preservation was possible in 18 patients.
  • Seventy-nine patients were alive at the time of completing the study.
  • [MeSH-major] Carcinoma / surgery. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922101.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Chedid HM, Lehn CN, Rapoport A, Amar A, Franzi SA: Assessment of disease-free survival in patients with laryngeal squamous cell carcinoma treated with radiotherapy associated or not with chemotherapy. Braz J Otorhinolaryngol; 2010 Mar-Apr;76(2):225-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of disease-free survival in patients with laryngeal squamous cell carcinoma treated with radiotherapy associated or not with chemotherapy.
  • In early stage (I and II) laryngeal squamous cell carcinoma, both surgery and radiotherapy results in significant local and regional control.
  • In advanced tumors (III and IV), radiotherapy alone has local-regional control rates of 32-43%.
  • AIM: To assess disease-free survival in SCC laryngeal carcinoma patients submitted to radiotherapy alone and/or associated with chemotherapy.
  • MATERIALS AND METHODS: Retrospective study involving 84 cases of laryngeal SCC treated with radiotherapy or chemotherapy together with radiotherapy.
  • In the second group, 11 cases were EC III and 20 IV.
  • Five-year disease-free survival was of 42.5%; 62.5% of the patients with organ preservation indication and 9.75 in the group of irressecable disease.
  • CONCLUSION: Disease-free survival of those patients submitted to radiotherapy because of laryngeal SCC was of 62.5%.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549084.001).
  • [ISSN] 1808-8686
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


78. Thakur JS, Minhas RS, Mohindroo NK, Sharma DR, Mohindroo S, Thakur A: Primary non-Hodgkin's lymphoma of the infratemporal fossa: a rare case report. Head Neck Oncol; 2009;1:20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATION: We present a case of a 41-year-old female that presented with swelling in the right preauricular region that had persisted for the past two years.
  • The tumor was excised and again the patient underwent chemotherapy.
  • The patient remained symptomatic and developed a second primary squamous cell carcinoma in the right retromolar trigone.
  • Extranodal NHL that is limited to a single site can be managed by surgery and regular follow up.
  • To the best of our knowledge, this is only the second case of primary NHL of the infratemporal fossa to be reported in the literature.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Skull Neoplasms / pathology. Temporal Bone
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngology. 1978 Sep-Oct;86(5):ORL-704-9 [114932.001]
  • [Cites] J Laryngol Otol. 1982 Sep;96(9):817-36 [7153645.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):433-7 [6486307.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Otolaryngol Clin North Am. 1986 Nov;19(4):685-710 [3540797.001]
  • [Cites] Laryngoscope. 1987 Mar;97(3 Pt 1):291-300 [3821348.001]
  • [Cites] Indian J Med Sci. 2006 Apr;60(4):159-61 [16679633.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):418-29 [3496014.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] J Laryngol Otol. 1996 Feb;110(2):161-2 [8729503.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Dec;123(12):1318-23 [9413361.001]
  • [Cites] Auris Nasus Larynx. 1999 Apr;26(2):201-5 [10214901.001]
  • [Cites] Radiother Oncol. 1987 Mar;8(3):199-207 [3575786.001]
  • (PMID = 19545392.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2711953
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


79. Lu S, Xu W, Fan Z, Liu W, Li J, Wang H: Overexpression of Smac/DIABLO in Hep-2 cell line: possible role in potentiating the sensitivity of chemotherapeutic drugs. Tumori; 2010 Mar-Apr;96(2):310-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Smac/DIABLO in Hep-2 cell line: possible role in potentiating the sensitivity of chemotherapeutic drugs.
  • AIMS AND BACKGROUND: The major obstacles for tumor chemotherapy are drug resistance and/or adverse effects on the host.
  • In the present study we investigated the role of the second mitochondria-derived activator of caspase (Smac/DIABLO) in the action of cisplatin (DDP), 5-fluorouracil (5-FU), and the combination of both in Hep-2 cells.
  • METHODS AND STUDY DESIGN: Hep-2 laryngeal carcinoma cells exposed to DDP, 5-FU and the combination of both were investigated.
  • Cell viability was determined by MTT assay.
  • RESULTS: DDP, 5-FU and the combination of both drugs reduced the cell survival rates in a concentration- and time-dependent manner.
  • The drug combination not only exerted a stronger inhibitory effect, but also at a lower concentration compared with the single drugs.
  • The expression of Smac/DIABLO increased significantly at both mRNA and protein levels after cell exposure to the combination compared with single drugs.
  • CONCLUSIONS: Smac/DIABLO plays a pivotal role in attaining a synergistic effect in Hep-2 cells in response to this combined strategy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / physiology. Laryngeal Neoplasms / drug therapy. Mitochondrial Proteins / physiology
  • [MeSH-minor] Caspase 3 / analysis. Caspase 9 / analysis. Cell Line, Tumor. Cell Survival / drug effects. Cisplatin / pharmacology. Flow Cytometry. Fluorouracil / pharmacology. Humans. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20572591.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Wycliffe ND, Grover RS, Kim PD, Simental A Jr: Hypopharyngeal cancer. Top Magn Reson Imaging; 2007 Aug;18(4):243-58
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal cancer.
  • Hypopharyngeal cancers are usually squamous cell carcinomas (SCCs) that has the worst prognosis among the head and neck cancers.
  • Overall, 5-year survival rate remains poor despite recent improvements in diagnostic imaging, radiation and chemotherapy, and improved surgical techniques.
  • The most important features determining prognosis are the size and extent of local spread of the primary carcinoma and the extent of involvement of regional lymph nodes.
  • Poor survival rate is partly due to emergence of second primary cancers but also to development of distant metastasis.
  • Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) remain the mainstay of initial radiological evaluation of hypopharyngeal cancer.
  • Imaging usually results in upstaging of the tumor at presentation.
  • Meticulous evaluation of the extent of the primary tumor with attention to spread to the subsites of the hypopharynx, larynx, and cartilage invasion are necessary for accurate staging.
  • After surgery and radiation therapy, it is difficult with CT and MR to differentiate residual and recurrent tumor from edema and scarring.
  • Fluorine 18-fluoro-deoxy-glucose -positron emission tomography (FDG-PET) has high sensitivity in detection of occult, residual, and recurrent tumors but has low specificity.
  • [MeSH-major] Hypopharyngeal Neoplasms / diagnosis. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893590.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 138
  •  go-up   go-down


81. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and distribution pattern of distant metastases in patients with ENT tumors and their consequences for pretherapeutic staging]. Strahlenther Onkol; 2007 Mar;183(3):138-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Häufigkeit und Topographie von Fernmetastasen bei Patienten mit HNO-Tumoren und ihre onsequenzen für das prätherapeutische Staging.
  • PATIENTS AND METHODS: 600 patients (526 men, 76 women, median age 56 years) with ENT tumors (squamous cell carcinoma histology) were studied retrospectively.
  • The distribution of primary tumor site and stage (AJCC) was as follows: oropharynx: n = 161 (26.8%), hypopharynx: n = 187 (31.2%), oral cavity: n = 89 (14.8%), larynx: n = 118 (19.7%), cancer of unknown origin: n = 13 (2.2%), others: n = 32(5.3%), I: n = 24 (4%), II: n = 49 (8.2%), III: n = 89 (14.8%), IV: n = 438 (73%).
  • The following parameters were analyzed in association with distant metastases: tumor localization, T- and N-category, primary treatment, local tumor control, and second neoplasms.
  • RESULTS: 114/600 patients (19%) developed distant metastases, 29/600 (4.9%) at presentation, 50% within 9.3 months after diagnosis of the primary tumor.
  • Distant metastases were most frequent in stage IV (24.2%), carcinoma of the hypopharynx (25.7%), local recurrence (24.3%), and second neoplasm (31.7%) with the following distribution pattern: pulmonary 61/114 (53.5%), pleural 15/114 (13.1%), osseous 45/114 (39.5%), hepatic 14/114 (12.3%), cerebral 8/114 (7%), cutaneous 14/114 (12.3%).
  • 82/600 (13.6%) patients additionally had second neoplasms, 20 corresponding with synchronous or metachronous bronchial tumors.
  • CONCLUSION: With locally advanced ENT tumor stage IVa/b, carcinoma of the hypopharynx, local recurrence or second neoplasms, at least a pretherapeutic CT of the thorax should be performed because every seventh patient (88/600) developed metastases or second primary tumors within the thoracic space during the course of disease.
  • Regarding the side effects and costs of curative therapy, the definition of generally accepted guidelines for the systemic staging of locally advanced ENT tumors should be undertaken.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Otorhinolaryngologic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Bronchogenic / pathology. Carcinoma, Bronchogenic / secondary. Combined Modality Therapy. Disease Progression. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / pathology. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340072.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Sriussadaporn S, Pak-art R, Sriussadaporn S: Small-diameter H-graft portacaval shunt for variceal hemorrhage: experience at King Chulalongkorn Memorial Hospital. J Med Assoc Thai; 2004 Apr;87(4):427-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Portosystemic shunts remain to be a good means for preventing recurrent variceal hemorrhage in a certain number of patients who fail to respond to other therapeutic modalities.
  • Distal splenorenal shunt is too technically demanding.
  • PTFE graft has been performed to prevent recurrent variceal hemorrhage in cirrhotic patients who failed to respond to long term pharmacotherapy and endoscopic therapy during the last 3 years at our institution.
  • Data analysis included: causes of cirrhosis, patients' Child-Pugh classification, operative time, operative blood transfusion, and results of treatment.
  • The operative time ranged from 225 to 420 minutes (mean 303, median 285 minutes).
  • One patient developed hepatic encephalopathy at 35 months postoperation which was thought to be secondary from progression of the hepatic parenchymal disease.
  • One patient developed recurrent variceal hemorrhage at 30 months postoperation from portal vein thrombosis and was successfully treated by endoscopic variceal sclerotherapy (EVS).
  • One patient died from carcinoma of the larynx 3 months after SDHGPCS and 2 died from end stage liver disease at 30 and 45 months after SDHGPCS.
  • The procedure is simple and practical to perform in hospitals with low volume of portosystemic shunt operations.
  • The authors recommended SDHGPCS as an alternative in prevention of recurrent variceal hemorrhage in cirrhotic patients who fail to respond to other therapeutic modalities.
  • [MeSH-major] Esophageal and Gastric Varices / surgery. Gastrointestinal Hemorrhage / surgery. Portacaval Shunt, Surgical
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Thailand

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217183.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


83. Sato H, Murai K, Kanda T, Mimura R, Hiratsuka Y: Association of chromium exposure with multiple primary cancers in the nasal cavity. Auris Nasus Larynx; 2003 Feb;30(1):93-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 56-year-old man who had worked at a chromate factory for 13 years developed squamous cell carcinoma of the left nasal cavity 11 years after retirement.
  • He received intra-arterial chemotherapy, followed by surgery.
  • Two years later, an adenocarcinoma was identified in the same nasal cavity just above the previous surgical region.
  • He underwent medial maxillectomy in combination with postoperative irradiation.
  • He has been disease free for 5 years after the second surgery.
  • Microsatellite markers were examined in the second tumor specimen as a possible factor for carcinogenesis; however, replication errors were not observed in any of four loci (D2S123, D3S1067, TP53, D18S474) tested.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Carcinoma, Squamous Cell / chemically induced. Chromium / adverse effects. Nasal Cavity / pathology. Neoplasms, Multiple Primary / chemically induced. Nose Neoplasms / chemically induced
  • [MeSH-minor] Humans. Male. Middle Aged. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589859.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0R0008Q3JB / Chromium
  •  go-up   go-down


84. Kim KM, Kim YM, Shim YS, Kim KH, Chang HS, Choi JO, Rho YS, Kim MS, Choi EC, Choi G, Sung MW, Kim SY, Lee YS, Baek JH, Kim SH, Kim YH, Im JH, Choi SH, Kim JH, Study Group of Korean Society of Head and Neck Surgeons: Epidemiologic survey of head and neck cancers in Korea. J Korean Med Sci; 2003 Feb;18(1):80-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This epidemiological survey on head and neck cancer patients was undertaken from January to December 2001 in 79 otorhinolaryngology resident-training hospitals nationwide.
  • The number of head and neck cancer patients was 1,063 cases in the year.
  • The largest proportion of cases arose in the larynx, as many as 488 cases, which accounted for 45.9%.
  • Surgery was the predominant treatment modality in head and neck cancers: 204 (21.5%) cases were treated with only surgery, 198 (20.8%) cases were treated with surgery and radiotherapy, 207 cases (21.8%) were treated with combined therapy of surgery, radiotherapy, and chemotherapy.
  • Larynx and hypopharynx cancers had a stronger relationship with smoking and alcohol drinking than other primary site cancers.
  • Of them, 21 cases were found to be metastasized at the time of diagnosis into the lung, gastrointestinal tract, bone, or brain.
  • Coexisting second primary malignancies were found in 23 cases.
  • At the time of diagnosis, a total of 354 cases had cervical lymph node metastasis accounting for 42.0%.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Head and Neck Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alcohol Drinking / epidemiology. Child. Female. Health Surveys. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Second Primary / epidemiology. Occupations. Registries / statistics & numerical data. Risk Factors. Smoking / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589092.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054997
  •  go-up   go-down


85. Almadori G, Bussu F, Navarra P, Galli J, Paludetti G, Giardina B, Maurizi M: Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia. Cancer; 2006 Jul 15;107(2):328-36
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot phase IIA study for evaluation of the efficacy of folic acid in the treatment of laryngeal leucoplakia.
  • BACKGROUND: It has been previously observed that patients with head and neck squamous cell carcinoma or with laryngeal leucoplakia present a significant reduction in plasma folate levels.
  • The current Phase IIA pilot study assessed the effectiveness of folic acid as a chemopreventive agent in patients affected by glottic laryngeal leucoplakia.
  • METHODS: Forty-three untreated patients affected by glottic laryngeal leucoplakia were enrolled in the Ear, Nose, and Throat Department (Universita Cattolica del Saco Cuore, Rome, Italy).
  • Glottic leucoplakia was initially diagnosed by indirect laryngoscopy and successively confirmed by diagnostic direct microlaryngoscopy with a biopsy for histologic assessment.
  • CONCLUSIONS: The larynx is 1 of the sites of major interest and a good model for the development of chemopreventive agents, but so far the proposed agents have shown no clear efficacy on precancerous lesions or on the development of second malignancies.
  • [MeSH-major] Folic Acid / therapeutic use. Laryngeal Neoplasms / drug therapy. Leukoplakia / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Laryngoscopy. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770770.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


86. Dietz A, Nollert J, Eckel H, Volling P, Schröder M, Staar S, Conradt C, Helmke B, Dollner R, Müller RP, Wannenmacher M, Weidauer H, Rudat V: [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. HNO; 2002 Feb;50(2):146-54
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study].
  • [Transliterated title] Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie. Ergebnisse einer multizentrischen Phase-II-Studie.
  • INTRODUCTION: Regarding the promising results of international trials we conducted the first German prospective multicentre phase II trial for organ preservation with primary simultaneous chemoradiation in advanced laryngeal and hypopharyngeal cancer.
  • PATIENTS AND METHODS: 28 of 30 recruited patients suffering from stage II and III (UICC) laryngeal and hypopharyngeal cancer were treated with primary simultaneous chemoradiation within an organ preservation program and monitored in follow-up of one year.
  • Exclusion criteria included tumor infiltration of the laryngeal cartilage, bilateral neck nodes (N2c) and need for flap reconstruction in case of laryngectomy.
  • The protocol included an accelerated concomitant boost chemoradiation (66 Gy) with Carboplatinum (70 mg/m2 1st and 5th week) and a restaging procedure one month after therapy.
  • RESULTS: After follow-up of one year 20 of 28 patients (71%) were presented with stable complete remission and functionally preserved larynx.
  • Of these 20 patients 3 developed pulmonary metastases, 1 secondary primary carcinoma of the lung and 3 neck metastases which needed neck dissections.
  • The other patients showed in 4 cases relapsing tumor which was indicated for laryngectomy.
  • One patient needed tracheotomy because of persisting edema and 2 patients died due to tumor progress.
  • Further studies should focus on the improvement of patient selection which could be realized by induction Chemotherapy (using new components like taxan) and/or use of prediction factors such as tumor volume and hemoglobin levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] HNO. 2002 Feb;50(2):109-13 [12080620.001]
  • (PMID = 12080625.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


87. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA: Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2010 Feb 1;76(2):403-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: Intensification of radiotherapy and chemotherapy for head-and-neck cancer may lead to increased rates of dysphagia.
  • METHODS AND MATERIALS: From an institutional database, 83 patients were identified who underwent definitive intensity-modulated radiotherapy for squamous cell carcinoma of the head and neck, after exclusion of those who were treated for a second or recurrent head-and-neck primary lesion, had locoregional recurrence at any time, had less than 12 months of follow-up, or had postoperative radiotherapy.
  • RESULTS: Mean dose greater than 41 Gy and volume receiving 60 Gy (V(60)) greater than 24% to the larynx were significantly associated with PEG tube dependence and aspiration.
  • V(65) greater than 33% to the superior pharyngeal constrictor or greater than 75% to the middle pharyngeal constrictor was associated with pharyngoesophageal stricture requiring dilation.
  • CONCLUSIONS: Doses to the larynx and pharyngeal constrictors predicted long-term swallowing complications, even when controlled for other clinical factors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheterization / utilization. Deglutition. Esophageal Stenosis / etiology. Esophageal Stenosis / therapy. Female. Gastrostomy / utilization. Humans. Male. Middle Aged. Pharyngeal Diseases / etiology. Pharyngeal Diseases / therapy. Radiotherapy Dosage. Retrospective Studies. Tumor Burden. Young Adult


88. Rózga A, Kurnatowska AJ, Raczyńsak-Witońska G, Loga G: [Evalution of activity of acid aspartic proteinase in Candida strains isolated from oral cavity of patients with increased risk of mycosis]. Wiad Parazytol; 2001;47(4):883-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first group comprised patients with cancer of the larynx qualified for surgery, the second- patients with neoplastic disease ( Hodgkin s disease, lymphoma, acute granulocytic leukaemia, lymphatic leukaemia, lung cancer, multiple myeloma, stomach cancer, breast cancer) who were not treated, the third group- patients with neoplastic diseases treated by chemotherapy.
  • [MeSH-minor] Humans. Mycological Typing Techniques. Risk Assessment. Risk Factors. Virulence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886442.001).
  • [ISSN] 0043-5163
  • [Journal-full-title] Wiadomości parazytologiczne
  • [ISO-abbreviation] Wiad Parazytol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 3.4.23.- / Aspartic Acid Endopeptidases
  •  go-up   go-down


89. Issing WJ: [Gastroesophageal reflux -- a common illness?]. Laryngorhinootologie; 2003 Feb;82(2):118-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a long time heartburn was not considered a symptom for serious illness.
  • By now, however, it is accepted that the incidence of secondary carcinoma of the esophagus caused by chronic GERD has increased dramatically since the nineteen-seventies.
  • Mechanisms leading to GERD are complex and its incidence is not necessarily pathological.
  • Laryngopharyngeal reflux (LPR) often results in atypical manifestations with oral, pharyngeal, laryngeal, and pulmonary disorders.
  • Laryngopharyngeal reflux is known to contribute to posterior acid laryngitis and laryngeal contact ulceration or granuloma formation, laryngeal cancer, chronic hoarseness, pharyngitis, asthma, pneumonia, nocturnal choking, and dental diseases.
  • Today, PPI are the medication of choice in both acute and long-term (prophylactic) therapy of GERD.
  • The so called "step-up-strategy" of medication is no longer recommended.
  • Only in the case of persisting symptoms medication was further increased to high-dose PPI therapy.
  • In the past this increase in medication lead to a prolonged healing process and consequently to higher medication costs.
  • Studies have shown that a "step-down"-therapy, beginning with high dose PPI, is highly preferable, since it is much more effective.
  • Depending on the degree of the symptoms, however, medication may also be applied "on-demand".
  • The BfArM has approved this kind of medication application only for Esomeprazol (Nexium mups 20 mg).
  • [MeSH-minor] Anti-Ulcer Agents / administration & dosage. Cross-Sectional Studies. Humans. Incidence. Laryngitis / drug therapy. Laryngitis / epidemiology. Laryngitis / etiology. Proton Pump Inhibitors


90. León X, López M, García J, Quer M: [Results of an organ conservation protocol in patients with locally advanced laryngeal tumours]. Acta Otorrinolaringol Esp; 2009 May-Jun;60(3):176-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of an organ conservation protocol in patients with locally advanced laryngeal tumours].
  • [Transliterated title] Resultados de un protocolo de preservación de órgano en pacientes con tumores localmente avanzados de la laringe.
  • INTRODUCTION AND OBJECTIVES: Advanced laryngeal carcinoma patients, candidates for total laryngectomy, nowadays have different treatment options.
  • One of them is induction chemotherapy, which allows modulation of the second manoeuvre according to the degree of response achieved.
  • This study presents the results of a large series of patients treated according to this protocol.
  • METHODS: Retrospective study of 370 patients with T3-T4 carcinomas of the larynx considered as candidates for total laryngectomy.
  • RESULTS: Seven patients died as a consequence of the treatment with chemotherapy.
  • Among 363 patients finishing chemotherapy, 154 (43 %) achieved complete response and proceeded with radiotherapy.
  • Total laryngectomy was performed in 135 (37 %) non-responders and 74 (20 %) patients were treated with radiotherapy in spite of an incomplete response to chemotherapy.
  • Larynx preservation was achieved in 42 % of the patients, rising to 72 % for complete responders to chemotherapy and to 62 % in non-responders receiving radiotherapy.
  • CONCLUSIONS: Our larynx preservation protocol including induction chemotherapy for patients with advanced carcinomas who are candidates for total laryngectomy achieved a total survival rate of 73 % with a 42 % larynx preservation rate.
  • The response to the induction chemotherapy was the factor contributing most to larynx preservation.
  • [MeSH-major] Laryngeal Neoplasms / therapy
  • [MeSH-minor] Aged. Clinical Protocols. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558903.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


91. Zimmer-Nowicka J, Kaczmarczyk D, Chudobiński C, Kubiak R, Niedźwiecka I, Morawiec-Bajda A: [Diagnostic problems in a case of the pyriform sinus carcinoma in a man]. Otolaryngol Pol; 2008;62(4):442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic problems in a case of the pyriform sinus carcinoma in a man].
  • Despite a use of many diagnostic tools to assess the stage of the carcinoma of hypopharynx and larynx various problems can still arise.
  • A 45 years old man was admitted with an initial diagnosis of carcinoma of the hypopharynx with metastases to neck lymphnodes (Tin situ N1).
  • Computed tomography of the neck revealed pathologic remodeling of the thyroid cartilage.
  • An oncologist decided to commence a chemotherapy.
  • After 4 cycles of chemotherapy a second CT scan revealed a suspected neoplastic infiltration of the cricoid and thyroid cartilages.
  • After that the patients was disqualified from both radio- and chemotherapy.
  • The consulting laryngologist did not find any pathologies in the larynx and hypopharynx.
  • The second specimen taken from the right pyriform sinus was a loosen fragment of the epithelium with the Ca male differentiatum G3.
  • The positron emission tomography imaging found a suspected site 11 mm in diameter situated in front of the carotid vessels.
  • The neoplastic infiltration of the larynx was not confirmed.
  • We are of the opinion that in the presented case the erroneous interpretation of the CT scan was a likely consequence of the improper setting of a window of brightness and contrast.
  • Another cause of the diagnostic problems could stem form an unfinished calcification of the cartilages which produced an image of irregular areas of calcification and rarely diagnosed T in situ in a pyriform sinus.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Hypopharynx / radiography
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837220.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


92. Chen W, Guo X, Luan X, Zhang C: [Long-term follow-up observation of clinical therapy for laryngeal carcinoma recurrence and cervical metastasis]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2004 Sep;18(9):536-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term follow-up observation of clinical therapy for laryngeal carcinoma recurrence and cervical metastasis].
  • OBJECTIVE: To observe the long-term effects of clinical treatment for laryngeal carcinoma recurrence and cervical metastasis, and discuss the operative therapy method for laryngeal carcinoma recurrence and cervical metastasis.
  • METHOD: Retrospective analysis the 70 patients with laryngeal carcinoma recurrence and cervical metastasis who was cured in our hospital from 1990 to 1998, including 31 local recurrence, 15 stomal recurrence and 24 cervical lymph node metastasis.
  • Twenty-eight patients who received the second-time operation survived over 5 years.
  • In 31 patients with local recurrence, 19 patients received total laryngectomy and 15 patients of them are now living, but 12 patients who did not accept surgical therapy were died in 1-3 years separately; 9 patients with stomal recurrence received the second-time operation and 5 of them lived 5 years longer, however, the 6 patients with stomal recurrence who did not accept the second-time operation all died in 18 months; In 24 patients with cervical lymph node metastasis, 15 patients received the neck dissection and 8 of them are now alive, but the rest patients who did not accept the operation died in 2 years.
  • CONCLUSION: Regular re-examination and systemic clinical follow-up studying are very important for early detection and early treatment in laryngeal carcinoma recurrence and cervical metastasis; Second-time surgical operation is an effective therapeutic method for laryngeal carcinoma recurrence and cervical metastasis; Radiotherapy and chemotherapy play a limited role in clinical therapy for laryngeal carcinoma recurrence and cervical metastasis.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696949.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Paludetti G, Almadori G, Bussu F, Galli J, Cadoni G, Maurizi M: Hypofolatemia as a risk factor for head and neck cancer. Adv Otorhinolaryngol; 2005;62:12-24
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofolatemia as a risk factor for head and neck cancer.
  • Head and neck cancer (HNSCC) includes squamous cell carcinomas of the oral cavity, pharynx and larynx.
  • The standard therapeutic approach, focused on surgery, irradiation and chemotherapy, alone or in combination, has been in part modified in the last 30 years, but the overall survival of HNSCC patients has not substantially improved.
  • To characterize and thus identify high-risk mucosal areas and preclinical tumors, molecular abnormalities in head and neck carcinogenesis have been extensively studied.
  • Nevertheless, we know that metabolic alterations, often aspecific, are frequently associated with cancer.
  • These may be secondary or may precede tumor development and favorite progression.
  • In particular, based upon our results, a role for folate deficiency as a risk factor in head and neck carcinogenesis seems plausible.
  • Homocysteine levels in cancer patients are probably largely affected by the HNSCC phenotype.
  • An accumulation of homocysteine might reveal a genetic defect which is theoretically a target for pharmacological therapy, for example by antifolic drugs.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Glutamate Carboxypeptidase II / blood. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Homocysteine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy, Needle. Case-Control Studies. Cohort Studies. Female. Humans. Immunohistochemistry. Italy / epidemiology. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Neoplasm Staging. Prognosis. Reference Values. Risk Factors. Sensitivity and Specificity. Smoking / adverse effects. Smoking / epidemiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608414.001).
  • [ISSN] 0065-3071
  • [Journal-full-title] Advances in oto-rhino-laryngology
  • [ISO-abbreviation] Adv. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0LVT1QZ0BA / Homocysteine; EC 3.4.17.21 / Glutamate Carboxypeptidase II
  •  go-up   go-down


94. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol; 2010 Jan;11(1):21-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
  • BACKGROUND: Previous results from our phase 3 randomised trial showed that adding cetuximab to primary radiotherapy increased overall survival in patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN) at 3 years.
  • METHODS: Patients with LASCCHN of the oropharynx, hypopharynx, or larynx with measurable disease were randomly allocated in a 1:1 ratio to receive either comprehensive head and neck radiotherapy alone for 6-7 weeks or radiotherapy plus weekly doses of cetuximab: 400 mg/m(2) initial dose, followed by seven weekly doses at 250 mg/m(2).
  • Randomisation was done with an adaptive minimisation technique to balance assignments across stratification factors of Karnofsky performance score, T stage, N stage, and radiation fractionation.
  • The primary endpoint was locoregional control, with a secondary endpoint of survival.
  • Following discussions with the US Food and Drug Administration, the dataset was locked, except for queries to the sites about overall survival, before our previous report in 2006, so that an independent review could be done.
  • Following completion of treatment, patients underwent physical examination and radiographic imaging every 4 months for 2 years, and then every 6 months thereafter.
  • INTERPRETATION: For patients with LASCCHN, cetuximab plus radiotherapy significantly improves overall survival at 5 years compared with radiotherapy alone, confirming cetuximab plus radiotherapy as an important treatment option in this group of patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Exanthema / chemically induced. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Cetuximab. Chemotherapy, Adjuvant. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Risk Assessment. Severity of Illness Index. Survival Analysis. Time Factors. Treatment Outcome


95. Lorenz KJ, Maier H: Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. Eur Arch Otorhinolaryngol; 2009 Dec;266(12):1937-44
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients.
  • Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin and mucosa.
  • After the injection of a photosensitizing agent, the tumour area is exposed to non-thermal laser light.
  • This causes a phototoxic reaction, producing oxygen radicals that destroy tumour cells.
  • From November 2003 to July 2007, a total of 35 patients with recurrent squamous cell carcinoma or secondary tumours of the head and neck region were treated with PDT at the German Armed Forces Hospital in Ulm.
  • These patients had failed or found unsuitable for other treatments.
  • Meta-tetrahydroxyphenylchlorin (mTHPC), known under the trade name of Foscan, was used as the photosensitizing agent.
  • Local control was achieved in 21 patients (60%) and partial remission in 10 patients (28.5%).
  • Four patients (11.5%) did not respond to PDT treatment.
  • The mean duration of overall survival was 401.45 (+/-321.2) days, median was 356 after the completion of treatment.
  • The mean duration of recurrence-free survival was 327.7 (+/-131.1) days, median was 181 for patients with complete remission.
  • None of the patient developed serious complications.
  • Photodynamic therapy is an important treatment option for patients who present with recurrent carcinoma or secondary tumours of the upper aerodigestive tract and who have failed or unsuitable for other treatments.
  • Due to the excellent treatment results that have been achieved so far, PDT may in the future also play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):239-44 [9612189.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Aug;18(8):707-12 [6891321.001]
  • [Cites] Methods Enzymol. 1984;105:36-47 [6727677.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] HNO. 1999 Oct;47(10):885-92 [10550372.001]
  • [Cites] HNO. 1995 Jun;43(6):364-70 [7642397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):573-8 [3516952.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):709-11 [12874068.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 May;127(5):489-93 [11346422.001]
  • [Cites] Onkologie. 2003 Dec;26(6):568-72 [14709932.001]
  • [Cites] HNO. 2004 Feb;52(2):175-192 [28246683.001]
  • [Cites] Head Neck. 2004 Mar;26(3):232-40 [14999798.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Oncology. 2002;63(2):145-50 [12239449.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1140-5 [8289004.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):138-46 [15185355.001]
  • [Cites] HNO. 1999 Dec;47(12):1058-62 [10654183.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):372-82 [14969816.001]
  • [Cites] Onkologie. 2001 Jun;24(3):230-7 [11455215.001]
  • [Cites] Radiother Oncol. 1995 Aug;36(2):94-100 [7501817.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):399-403 [8164476.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(3):164-7 [10839492.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Int J Cancer. 1995 Oct 9;63(2):198-204 [7591204.001]
  • [Cites] Laryngorhinootologie. 2005 Oct;84(10):725-32 [16231239.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1261-5 [8906063.001]
  • [Cites] Br J Cancer. 2002 Dec 2;87(12):1470-8 [12454779.001]
  • (PMID = 19290535.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


96. Hehr T, Classen J, Welz S, Ganswindt U, Scheithauer H, Koitschev A, Bamberg M, Budach W: Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. Radiother Oncol; 2006 Jul;80(1):33-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
  • BACKGROUND: To determine the outcome, acute and late toxicity in locally advanced head and neck cancer stage IVA with mitomycin-C (MMC), cisplatin (DDP) chemotherapy and hyperfractionated accelerated radiation therapy (C-HART).
  • PATIENTS AND METHODS: Thirty-five patients, with squamous cell cancer of the oral cavity (20%), oropharynx (37%), hypopharynx (26%) and larynx (17%), received 30 Gy (2 Gy every day) followed by 1.4 Gy bid to a total of 70.6 Gy concurrently with MMC 10mg/m(2) (day 1 plus 36) and DDP 6 mg/m(2) given Mondays through Fridays during weeks 1-3.
  • At 3 years the locoregional control and survival rates were 60% and 46%, respectively.
  • Mucositis is a frequent, severe toxicity in patients treated with C-HART for head and neck cancer.
  • While it appears that mucositis and hematological toxicity may lead to hospitalization and omitting of the second dose of mitomycin C, its impact on radiotherapy interruptions is marginal.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / pharmacology. Combined Modality Therapy / methods. Dose Fractionation. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Mitomycin / pharmacology
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Female. Humans. Male. Middle Aged. Prospective Studies. Radiation-Sensitizing Agents / pharmacology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875750.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Radiation-Sensitizing Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


97. Hanna E, Alexiou M, Morgan J, Badley J, Maddox AM, Penagaricano J, Fan CY, Breau R, Suen J: Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg; 2004 Jul;130(7):861-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
  • OBJECTIVES: To evaluate the efficacy and toxic effects of intensive chemoradiotherapy as a primary modality for organ preservation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to define the patterns of treatment failure associated with this therapy.
  • SETTING: Tertiary care referral center.
  • MAIN OUTCOME MEASURES: Efficacy data included the rates of tumor response to therapy, organ preservation, disease recurrence, overall and disease-specific survival, and patterns of treatment failure.
  • Toxic effect data included the rate and grade of treatment-related complications and the rate of unscheduled hospital admissions for managing treatment-related toxic effects.
  • Average age at diagnosis was 62 years (range, 37-85 years).
  • The primary tumor site was the oropharynx in 58 patients (46%), the larynx in 36 (28%), the hypopharynx in 20 (16%), the oral cavity in 10 (8%), and another site in 3 (2%).
  • Primary chemoradiotherapy achieved complete response at the primary tumor site in 109 patients (86%).
  • Overall, at mean follow-up of 3 years, local disease control was achieved in 113 patients (89%), and organ preservation was possible in 102 patients (80%).
  • Overall, at an average follow-up of 36 months, regional disease control was achieved in 76 (92%) of the 83 patients with neck metastasis.
  • Despite this high locoregional control rate, distant metastasis occurred in 18 patients (14%), was the most common site of disease recurrence (53%), and accounted for almost 40% of all treatment failures.
  • Two patients (2%) died of treatment-related toxic effects.
  • Most deaths were due to distant metastasis, comorbidity, and second primary tumors.
  • CONCLUSIONS: High rates of locoregional disease control and organ preservation are achievable with primary chemoradiotherapy in patients with advanced SCCHN, but they are associated with severe treatment-related toxic effects.
  • Despite this effective local and regional disease control, improved survival is hampered by the relatively high incidence of distant metastasis, second primary tumors, and comorbidity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arkansas / epidemiology. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262764.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


98. Tejedor M, Valerdi JJ, Arias F, Dominguez MA, Pruja E, Mendez L, Illarramendi JJ: Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma. Cytokines Cell Mol Ther; 2000 Mar;6(1):35-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma.
  • An open-label, non-randomized study evaluated the feasibility and efficacy of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r-metHuG-CSF) to prevent mucositis induced by accelerated hyperfractionated radiotherapy (1.6 Gy b.i.d., total dose 67.2 Gy in six weeks with a two-week split) and concomitant chemotherapy (cisplatin, 20 mg/m2/day, days 1-5 by continuous intravenous infusion) in patients with laryngeal carcinoma.
  • Filgrastim 300 microg/day was administered on days 1, 3, and 5 in weeks 2-6 of radiotherapy, after the second fraction.
  • Nineteen patients (95%) completed the treatment in the planned time.
  • The administration of filgrastim with this regimen was feasible, and it appeared to reduce the severity and duration of mucositis induced by the combined treatment.
  • [MeSH-major] Cisplatin / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Laryngeal Neoplasms / therapy. Mouth Mucosa / radiation effects. Radiation Injuries / prevention & control. Stomatitis / prevention & control
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Filgrastim. Humans. Infusions, Intravenous. Male. Middle Aged. Recombinant Proteins. Survival Rate

  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976537.001).
  • [ISSN] 1368-4736
  • [Journal-full-title] Cytokines, cellular & molecular therapy
  • [ISO-abbreviation] Cytokines Cell. Mol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


99. Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S, Arora B, Sharma D, Kurkure PA, Ramadwar M, Viswanathan S, Rangarajan V, Qureshi S, Deshpande DD, Shrivastava SK, Dinshaw KA: Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):728-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy.
  • PURPOSE: To evaluate the efficacy of intensity-modulated radiotherapy (IMRT) in reducing the acute toxicities associated with conventional RT (CRT) in children with nasopharyngeal carcinoma.
  • PATIENTS AND METHODS: A total of 36 children with nonmetastatic nasopharyngeal carcinoma, treated at the Tata Memorial Hospital between June 2003 and December 2006, were included in this study.
  • Of the 36 patients, 28 were boys and 8 were girls, with a median age of 14 years; 4 (11%) had Stage II and 10 (28%) Stage III disease at presentation.
  • All patients had undifferentiated carcinoma and were treated with a combination of chemotherapy and RT.
  • RESULTS: After a median follow-up of 27 months, the 2-year locoregional control, disease-free, and overall survival rate was 76.5%, 60.6%, and 71.3%, respectively.
  • A significant reduction in acute Grade 3 toxicities of the skin (p = 0.006), mucous membrane (p = 0.033), and pharynx (p = 0.035) was noted with the use of IMRT.
  • The median time to the development of Grade 2 toxicity was delayed with IMRT (skin, 35 vs. 25 days, p = 0.016; mucous-membrane, 39 vs. 27 days, p = 0.002; and larynx, 50 vs. 28 days, p = 0.009).
  • The duration of RT significantly influenced disease-free survival on multivariate analysis (RT duration >52 days, hazard ratio = 5.49, 95% confidence interval, 1.14-26.45, p = 0.034).
  • The average mean dose to the first and second planning target volume was 71.8 Gy and 62.5 Gy with IMRT compared with 66.3 Gy (p = 0.001) and 64.4 Gy (p = 0.046) with CRT, respectively.
  • CONCLUSION: The results of our study have shown that IMRT significantly reduces and delays the onset of acute toxicity, resulting in improved tolerance and treatment compliance for children with nasopharyngeal carcinoma.
  • Also, IMRT provided superior target coverage and normal tissue sparing compared with CRT.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374512.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Galiana R, Boladeras A, Mesía R, Gómez J, de Juan A, Mañós M, Nogués J, Navarro V, Guedea F: Twice-a-day radiotherapy for head and neck cancer: the Catalan Institute of Oncology experience. Radiother Oncol; 2002 Jul;64(1):19-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twice-a-day radiotherapy for head and neck cancer: the Catalan Institute of Oncology experience.
  • PURPOSE: The purpose of this work is to evaluate the contribution of hyperfractionated radiotherapy (RT) in head and neck cancer by sub-localisation.
  • Fractions used were 1.2 Gy twice-a-day with a curative intent on all patients, to a total mean dose of 79.14 Gy.
  • Treatment protocols by localisation were: larynx: 55 patients with T2N0 and T1-2N1 tumours treated with only RT and 27 patients with T3N0-1 in complete remission after three cycles of induction chemotherapy (ICT); hypopharynx: 29 patients with T2-4N0-2b resectable tumors in response to three cycles of ICT; oropharynx: 48 patients with T2-3N0-1 and T1N1 tumours treated with only RT; 34 patients with nasopharynx tumours treated with RT and three cycles of ICT if T4 or >N1; finally, 125 patients with non-surgical tumours of any localisation treated with four cycles of induction CT and RT.
  • RESULTS: LARYNX: Actuarial local control (LC), disease-free survival (DFS) and overall survival (OS) at 5 years were 78, 73 and 48%, respectively, in T2 tumours and 75, 72 and 60% in stage III disease.
  • NON-SURGICAL TUMORS: Actuarial LC, DFS and OS at 5 years were 39, 33 and 19%, respectively.
  • A total of 47 patients (14.8%) of the overall group had a second tumour, 72% of them tobacco-related.
  • Only patients with nasopharynx tumours had a low incidence of second tumours.
  • CONCLUSIONS: Twice-a-day external RT can be effectively managed in patients with head and neck cancer.
  • Second neoplasm and intercurrent diseases become an important problem in low and medium stages whereas disease recurrences is the main problem in advanced stages.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Otorhinolaryngologic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiation Injuries. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ireland Ltd.
  • (PMID = 12208570.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down






Advertisement